IMMP / efti-pembrolizumab-soft-tissue-sarcoma — Eftilagimod alfa with pembrolizumab and radiotherapy, given before surgery for soft tissue sarcoma
Program analysis ·
bpiq_drug_id17452 · Mode A (prospective) · prepared 2026-10 · search date 2026-10-17 · USD · framework v6.2.0 · Coverage: CLEAREDAsset. Eftilagimod alfa (INN) · IMP321, “efti” · no brand name · Immutep Limited, through Immutep S.A.S.; the trial is run by the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw. Immutep keeps North America, Europe and Japan. Dr. Reddy’s Laboratories holds the other territories except Greater China, which EOC Pharma holds [1] Biology and modality. MHC class II on antigen-presenting cells · a soluble LAG-3 fusion protein that switches those cells on · modality
other(an Fc fusion protein, not an antibody) [2] Indication. Soft tissue sarcoma · given before surgery (neoadjuvant), resectable, non-metastatic, grade 2–3, limbs, girdles or superficial trunk · no biomarker subgroup · therapeutic areaoncology· orphan status US yes, EU unknown [3] [4] Status. Phase 2 · EFTISARC-NEO, NCT06128863, primary endpoint met in 2025 · FDA Orphan Drug Designation (2026-04-15) · no approval anywhere [3] [4] Launch markets. United States and the EU5 (Germany, France, Italy, Spain, United Kingdom), the markets Immutep keeps. Japan is also kept but is not modelled. No launch plan is announced [1] [5]Company context, financials, ownership, options and the full pipeline:
../company.md.How to read this. Written for a curious reader with little or no background in science, medicine, the drug industry or finance. Terms specific to this program are explained in the Glossary below. General terms are explained once in the glossary. All money figures are in US dollars (USD). Every fact carries one of three tags.
[VERIFIED — source]means a primary source confirmed it, and the source is named.[UNVERIFIED]means it could not be confirmed.[WEB ESTIMATE — source, date]means it is a third-party figure or a labelled model.Confidence legend. Every conclusion carries a confidence beside it (
01-rules.mdrule 1). A conclusion is a judgement drawn from several facts: a score, a rating, an answer to a Go / No-Go question, or a verdict. High means the evidence under it is primary, consistent and recent. Medium means the evidence is partial, indirect or mixed. Low means the judgement rests mostly on inference or on sources that could not be verified.Sources. Every source is cited as a number in square brackets,
[n]. The numbers run through the document in the order of first use. The Sources list at the end gives one link per number (01-rules.mdrule 20). “No public record as of 2026-10-17” means a search on that date found nothing.One unit change to know before reading any price. On 2026-09-28 the American Depositary Share (ADS) changed from 10 ordinary shares to 200 ordinary shares. One new ADS replaced twenty old ones. Every price in this document is on the new basis. The superseded 2026-08-19 record’s spot of US$0.40 equals US$8.00 on the new basis. See
../company.mdC.4.
Glossary
| Term | Plain-language meaning |
|---|---|
| Eftilagimod alfa (efti; earlier IMP321) | The drug. A manufactured, soluble copy of the outer part of the human immune protein LAG-3, joined to an antibody tail, injected under the skin. It does not block anything: it switches immune cells on. |
| LAG-3 (lymphocyte activation gene-3) | A protein on activated T cells that acts as a brake there. As a free-floating manufactured protein it does something else: it binds antigen-presenting cells and wakes them up. |
| MHC class II | A molecule on antigen-presenting cells that holds up protein fragments for T cells to inspect. Efti attaches to it. |
| Antigen-presenting cell (APC) | An immune cell, such as a dendritic cell or a monocyte, that shows T cells what a threat looks like. |
| Soft tissue sarcoma (STS) | A rare cancer that starts in muscle, fat, nerve or connective tissue. It is most often found in an arm, a leg or the trunk. |
| Neoadjuvant | Given before the operation that removes the tumour. Adjuvant means after surgery. |
| Resectable | The tumour can be removed by surgery. |
| FNCLCC grade | The French three-level grading of sarcoma aggressiveness, from 1 (least) to 3 (most). This trial took grades 2 and 3. |
| Hyalinization / fibrosis | What a treated tumour turns into when it dies in place: glassy scar tissue. A pathologist measures what share of the removed tumour has turned to scar. |
| Pathologic response | Judging treatment by looking at the removed tumour under a microscope. |
| Health-related quality of life (HRQoL) | What patients report about how they feel and function, on a standard questionnaire. This is what the October 2026 catalyst reports. |
| EORTC QLQ-C30 | The most widely used cancer quality-of-life questionnaire in Europe. Its global health status score runs 0–100, and higher is better. A change of about 10 points is conventionally treated as one patients notice. |
| ePoster | An electronic poster at a medical congress. The lowest-visibility format: no talk and no discussant. |
| EFTISARC-NEO | The trial: a 40-patient, single-arm, single-site Phase 2 study in Warsaw, testing efti added to pembrolizumab and radiotherapy before surgery. |
| SARC032 | The competitor precedent: a randomised trial of pembrolizumab added to radiotherapy before surgery in the same disease. It met its primary endpoint. |
| 200 L and 2,000 L scale | The size of the steel tanks the drug is grown in. Efti from the two sizes was found in 2026 to differ slightly in its sugar chains (N-glycans). |
| N-glycan | A sugar chain attached to a protein during manufacture. Small differences can change how a protein behaves in the body. |
Executive scorecard
Asset snapshot
| Asset snapshot | |
|---|---|
| Asset and sponsor | Eftilagimod alfa (IMP321), Immutep Limited. Trial sponsor: Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, with Immutep S.A.S. as collaborator. Immutep keeps North America, Europe and Japan; Dr. Reddy’s holds most other territories; EOC Pharma holds Greater China [1] [3] |
| Modality and mechanism | other: an Fc fusion protein. A soluble LAG-3 protein that binds MHC class II on antigen-presenting cells and switches them on. Key design feature: it is an agonist (it activates), unlike every other LAG-3 drug, which blocks [2] |
| Targeted indications (Mode A) or approved indications (Mode B) | Resectable, non-metastatic, grade 2–3 soft tissue sarcoma of the limbs, girdles or superficial trunk, before surgery, with radiotherapy and pembrolizumab. No biomarker selection [3] |
| Stage and mode | Phase 2 (primary endpoint met 2025) · Mode A |
| Next catalysts (Mode A) or commercial status (Mode B) | EFTISARC-NEO health-related quality-of-life abstract, online 2026-10-19 at 00:05 CEST; ePoster 3788eP at ESMO Congress 2026, Madrid, 23–27 October. Readout window 2026-10-19 (DAY, HIGH) [6] |
| Asset verdict | See the asset verdict below |
Domain scores
The weights are v2.2’s defaults [UNVERIFIED — default weight]. Every derived figure below was
computed by scorecard in lib/scorecard.mjs.
| Domain | Sections | Weight | Score (1–10) | Rating | Key driver (one line) |
|---|---|---|---|---|---|
| Scientific rationale | A.1–A.2 | 15% | 4.7 | amber | A clean safety record and a reproducible immune signal, against no human genetic support and one failed randomised test of the hypothesis |
| Clinical data and design | A.3 | 20% | 4.0 | amber | One 38-patient single-arm trial met a surrogate endpoint; no comparison against today’s pembrolizumab-plus-radiotherapy regimen |
| Regulatory pathway | A.4 | 10% | 4.0 | amber | Orphan Drug Designation held, but no agreed registrational endpoint or design |
| Operations and CMC | A.5, M | 10% | 4.0 | amber | Single-site uncontrolled design, and a 2026 finding that commercial-scale product differs from the product that worked |
| Competitive position | B.1 | 15% | 5.0 | amber | The only MHC class II agonist in the clinic, but years behind an add-on regimen that already has randomised data |
| Market access | B.2–B.3 | 15% | 3.2 | red | Single-arm surrogate data, no comparator and no payer precedent for an add-on in this setting |
| Risk profile (10 = low risk) | C | 15% | 3.0 | red | Unfunded registrational trial, a manufacturing comparability question and a backbone that works without the drug |
| Weighted total | 100% | 4.0 | amber |
Key metrics
| Key metric | Low | Base | High | Source or assumption [n] |
|---|---|---|---|---|
| Probability of success to the next phase (A.6) | 10% | 20% | 35% | A.6; base rate 24.6% [WEB ESTIMATE — BIO/Informa/QLS 2021] [7] |
| Probability of success to approval (A.6) | 2% | 5% | 10% | A.6; base rate 10.8% [WEB ESTIMATE — BIO/Informa/QLS 2021] [7] |
| Peak sales, USD per year (B.4a) | US$18M | US$75M | US$192M | B.4a, STS only, US and EU5, modelled [UNVERIFIED — modelled] |
| eNPV, USD (B.4b) | not computed | not computed | not computed | B.4b: the cost and design of the registrational trial are undisclosed |
| Market Access Score (B.3) | 3.2 | B.3, from lib/scorecard.mjs |
Top-3 box
- Top-3 value drivers. 1. The only MHC class II agonist in clinical development, with no grade 3 or higher toxicity attributed to it in this trial [3] [8]. 2. A met primary endpoint by a wide margin: median 51.5% hyalinization against a pre-specified 35% target [5]. 3. Orphan Drug Designation in the US, and since 2026-09-11 one of only two indications the company intends to take into registration-directed trials [4] [9].
- Top-3 risks, each with its mitigation. 1. The effect cannot be separated from the pembrolizumab-plus-radiotherapy backbone, which works on its own [10]. Mitigation: a randomised trial against that backbone, which is not yet designed or funded. 2. Manufacturing: the root cause analysis found that efti made at 2,000 L scale differs in its sugar chains from the 200 L product used in earlier positive trials [9]. Mitigation: a new 200 L run is contracted. 3. Financing: the next trials are targeted for 2H CY2027, “subject to … partnering and resources” [9]. Mitigation: about A$61M of cash net of debt-like items at 2026-06-30, and a licensing partner consulted on the plan.
- Evidence gaps, and whether each is still fixable at this stage. 1. No randomised comparison against pembrolizumab plus radiotherapy: fixable, only by the next trial. 2. No disease-free survival data yet: fixable, follow-up runs to 2027-04-30 [3]. 3. No peer-reviewed publication of EFTISARC-NEO seventeen months after the primary endpoint: fixable at any time.
Asset verdict
Asset verdict: Monitor. A genuinely novel mechanism with a clean safety record and a met surrogate endpoint in an orphan indication. The asset cannot be valued until a randomised trial against the current add-on regimen is designed and funded, and until the manufacturing question is closed. · confidence Medium
Visual 1: the seven domain scores

Source(s): the domain table above, computed by lib/scorecard.mjs from the scores in A.2, A.3,
A.4, A.5, M.6, B.1, B.3 and C [3] [5] [9] [10]
Visual 2: milestones

Source(s): CT.gov NCT06128863 [3]; Immutep releases and filings [1] [4] [5] [6] [9] [11] [12] [13]
Visual 2b: clinical study timeline

Source(s): dates and n from CT.gov [3] [14] [15] [16] [17] [18] [19] [20]; the efti plus avelumab stratum’s end date is its final-data presentation at ASCO 2021, from the BPIQ note on row 16013, approximated to the month [21]; the next trial’s bar is the company’s 2H CY2027 target [9]. Date basis: registry dates as of 2026-10-17. TACTI-004 is shown to its discontinuation, not to its registry date.
Studies supporting key target-profile claims.
- EFTISARC-NEO (NCT06128863): the efficacy, safety and regimen rows of A.1 [3] [5] [8].
- SU2C-SARC032 (NCT03092323): the standard-of-care and competitor column of A.1 [10].
- AIPAC (NCT02614833): the precedent that efti sustained quality of life in a randomised trial [22].
- TACTI-mel and the INSIGHT efti plus avelumab stratum: the 30 mg dose [2] [21].
- TACTI-004 (NCT06726265): the failed randomised test that sets the scientific risk [11].
Rationale for the clinical development plan. The neoadjuvant setting lets investigators see the drug’s effect in the removed tumour within weeks. EFTISARC-NEO was the cheap, fast first test of that idea. A registrational trial would have to compare efti plus pembrolizumab plus radiotherapy against pembrolizumab plus radiotherapy, with disease-free survival as the endpoint.
Key Go / No-Go to the next decision point. The next decision is the start of a registration-directed trial, targeted for 2H CY2027 [9]. Go criteria: the root cause analysis closes and a comparable product batch exists (D3); an endpoint and design are agreed with the FDA (P1); funding or a partner is secured (B.4c). No-go criteria: the HRQoL data show meaningful harm (this catalyst, 2026-10-19); disease-free survival in EFTISARC-NEO’s 24-month follow-up looks no better than SARC032’s (2027-04-30 or later); the 200 L product fails comparability (date not disclosed).
Clinical pharmacology studies
| Study (ID or NCT) | Type | Design and n | Key finding | Label or dosing impact | Source |
|---|---|---|---|---|---|
| TACTI-mel (NCT02676869) | Dose escalation (RP2D) | Phase 1, open-label, 1, 6 and 30 mg, n=24 | No dose-limiting toxicity; sustained exposure at 30 mg | 30 mg carried forward | [2] [20] |
| INSIGHT efti plus avelumab stratum | Dose escalation (RP2D) | Phase 1, 6 or 30 mg, n=12 | No dose-limiting toxicity; 30 mg set as the recommended Phase 2 dose | 30 mg every 2 weeks | [21] |
| — | Drug–drug interaction | not conducted | No public record as of 2026-10-17 | None | [23] |
| — | QTc | not conducted | No public record as of 2026-10-17 | None | [23] |
| — | Hepatic or renal impairment | not conducted | No public record as of 2026-10-17 | None | [23] |
| Pooled analysis of 5 trials | Population PK and exposure–response | Retrospective, pharmacodynamic only | Absolute lymphocyte count rose on efti; responders lived longer. No PK model published | None; an association, not an exposure–response model | [24] |
| AIPAC-003 (NCT05747794) | Dose optimisation | Randomised dose comparison under FDA Project Optimus | 30 mg selected as the optimal biological dose | Confirms 30 mg | [5] |
| TACTI-mel (NCT02676869) | Immunogenicity, food effect, ADME, ethnic bridging (as applicable) | Anti-efti antibodies assayed | Assayed; the result is not stated in the abstract. Food effect not applicable (injection). No ADME or bridging study found | None | [2] |
0. Program-tier coverage — CLEARED
| Tool | State | Note / verbatim error |
|---|---|---|
CT.gov search_trials + get_trial_details on the pivotal NCT | CALLED | search_trials on “eftilagimod”: 11 of 11 trials. get_trial_details on NCT06128863: full design, eight outcome measures, other_outcomes null, one site, no investigators listed. |
PubMed search_articles + get_article_metadata on every hit (if ≤15) | CALLED | 10 of 10 hits on “eftilagimod”, metadata for all ten, authors complete. The null-authors bug did not fire. No EFTISARC-NEO publication exists. One follow-up query hit Rate limit exceeded and cleared on retry. |
Open Targets search_entities | CALLED | Returned LAG3 (ENSG00000089692), soft tissue sarcoma (MONDO_0018078) and eftilagimod alfa (CHEMBL4594557). A follow-up association query found a LAG3 to soft tissue sarcoma score of 0.104, from literature (0.118) and clinical (0.165) evidence only, with no genetic association. Blocked on 2026-08-19; it answered this time. |
ChEMBL compound_search | CALLED | One record, CHEMBL4594557, max_phase 2, structure_type NONE, no selectivity data (a fusion protein). |
| web_search ×4: peak sales · competitive · exclusivity + royalty · analyst | CALLED | Peak sales: no STS-specific figure; one drug-wide figure, rejected (B.4a). Competitive: SARC032 is the only randomised precedent. Exclusivity and royalty: Dr. Reddy’s terms; no patent expiry found. Analyst: no target dated after June 2026; none used. |
| B.1a competitor efficacy and side-effect search (P4) | CALLED | SARC032 per-arm DFS and grade 3+ rates from the Lancet paper; EFTISARC-NEO from Immutep releases. |
| Orange Book and Purple Book | CALLED | Web search. Efti is unapproved, so no Purple Book entry [25]. Pembrolizumab’s core US patent is expected to expire in 2028 (secondary source). |
| DailyMed (API) | CALLED | Two pembrolizumab labels (Keytruda, 2026-07-24; Keytruda Qlex, 2026-08-12). No soft tissue sarcoma indication; sarcoma appears only inside the tumour-agnostic data tables. |
| ICER | CALLED | Web search. No ICER assessment of soft tissue sarcoma or of pembrolizumab in sarcoma found. |
| CMS Medicare drug price negotiation page | CALLED | Page read; the drug list sits on a sub-page not reached. A secondary source reports that pembrolizumab was not selected for 2028 because of the 2025 orphan-exclusion change. |
| payer tier EU joint clinical assessment | CALLED | Web search. No JCA of efti. JCA is mandatory for new oncology medicines filed from January 2025. |
| payer tier G-BA and IQWiG | CALLED | Web search. Closest analogue: olaratumab in soft tissue sarcoma, 2017 decision, rescinded 2020. |
| payer tier NICE | CALLED | Web search. TA465 (olaratumab, 2017) and TA185 (trabectedin, updated 2021). No neoadjuvant STS appraisal. |
| payer tier ICER | CALLED | As in the program-tier row. |
| payer tier Chuikyo | CALLED | Web search. Trabectedin was listed on Japan’s NHI price list on 2015-11-26; no cost-effectiveness record found. |
| manufacturing tier | Not applicable | Phase 2; the tier applies from Phase 3 (02-connectors.md § Manufacturing tier). |
| optional EDGAR full-text search on the drug’s names | NOT CALLED | Optional. The EDGAR filing feed was read at the company tier. |
optional Europe PMC search | NOT CALLED | Optional. PubMed returned cleanly. |
optional CTIS search | NOT CALLED | Optional. A web search surfaced the EU trial number 2024-515971-37-00 for EFTISARC-NEO. |
Company-tier coverage is in ../company.md C.0. It is CLEARED, with the optional
Yahoo options cross-check BLOCKED.
What the sweep does not cover. Open Targets answered this time, so the genetics leg of target validation is now a finding instead of a gap: there is no genetic association between LAG3 and soft tissue sarcoma [26]. That matters less than usual, because efti activates a pathway rather than blocking LAG-3. The 2026-08-19 version said the same thing about the cost of the block; that reasoning still holds.
A. Scientific and clinical value
A.1 Target product profile
Target label. Eftilagimod alfa, added to neoadjuvant radiotherapy and pembrolizumab, for adults with resectable, non-metastatic, grade 2–3 soft tissue sarcoma of the limbs, girdles or superficial trunk, with a primary tumour larger than 5 cm or any locally recurrent tumour [3].
| Attribute | Minimum viable | Competitive (base) | High case | Standard of care and key competitors, data [n] | Current evidence for efti [n] | Rating · confidence |
|---|---|---|---|---|---|---|
| Indication and population | The EFTISARC-NEO population | The same, across all histologies that receive neoadjuvant radiotherapy | All resectable high-grade STS before surgery | Radiotherapy then surgery; pembrolizumab added for undifferentiated pleomorphic sarcoma and liposarcoma subtypes, per SARC032 [10] | 40 patients, one site, mixed histologies (Ewing and rhabdomyosarcoma excluded) [3] | amber · Medium |
| Mechanism and differentiation | Adds immune activation without added toxicity | Shows an effect over pembrolizumab plus radiotherapy | The same, with a response biomarker | PD-1 blockade (pembrolizumab) [10]; LAG-3 blockade (relatlimab) approved in melanoma only [27] | The only MHC class II agonist in the clinic; its added effect over the backbone is not isolated [2] [27] | amber · Medium |
| Efficacy (primary and key secondary endpoints) | Disease-free survival no worse than pembrolizumab plus radiotherapy | Disease-free survival better than pembrolizumab plus radiotherapy | Overall survival benefit | SARC032: 2-year DFS 67% with pembrolizumab against 52% without; hazard ratio 0.61 (90% CI 0.39–0.96) [10] | Median hyalinization 51.5% (n=38) against a 35% target and about 15% historically with radiotherapy alone; no DFS data yet [5] [8] | red · Medium |
| Safety and tolerability | No more grade 3+ events than pembrolizumab plus radiotherapy | Fewer | No more wound complications than radiotherapy alone | SARC032: grade 3+ adverse events 56% with pembrolizumab, 31% without [10] | No grade 3+ toxicity attributed to efti or pembrolizumab; the all-cause rate is not disclosed [8] | green · Medium |
| Dose, regimen, route, formulation | Injections fit visits the patient already attends | Same | Fewer doses | Pembrolizumab intravenous every 3 weeks, or the subcutaneous Keytruda Qlex form [28] | 30 mg under the skin every 2 weeks for 9 weeks [3] [21] | green · High |
| Biomarker or companion diagnostic | None needed | None needed | A response marker | PD-L1 is not used to select sarcoma patients [10] | Interferon-gamma, CXCL9 and CXCL10 rose and tracked pathologic response; exploratory [5] [8] | amber · Low |
| Payer value (B.3) | Reimbursed as an add-on in an orphan setting | Positive HTA with quality-of-life support | Premium price | Pembrolizumab is reimbursed for many cancers; no HTA in neoadjuvant STS [28] | None. The October HRQoL data are the first evidence on this row (B.3) | red · Medium |
Stakeholder check
| Stakeholder | What they require | Does the competitive profile meet it? (tagged) | Basis [n] |
|---|---|---|---|
| Patient and caregiver | Benefit the patient notices; convenience | Not yet shown. Convenience is good: injections at visits already scheduled. A benefit patients notice needs relapse data [UNVERIFIED] | [3] |
| Regulator | A favourable balance of benefit against risk | Not met. No randomised trial and no agreed endpoint [VERIFIED — CT.gov search_trials, 2026-10-17] | [3] [9] |
| Payer and HTA body | Added benefit against the comparator, at a price they accept | Not met. The comparator would be pembrolizumab plus radiotherapy, and no comparison exists [VERIFIED — no comparative trial found] | [10] |
| Prescriber | A fit in treatment guidelines; ease of use | Partly. It fits the existing neoadjuvant workflow; it is in no guideline [UNVERIFIED] | [10] |
Value link. The illustrative oncology link is US$150–300M of peak sales per month of overall
survival gained [UNVERIFIED — illustrative] (framework/07-benchmarks.md § Rules of thumb). It
must be scaled down hard here. The population is about 6,000 patients a year in the modelled
markets (B.2), the relevant endpoint is disease-free survival rather than survival, and efti would
be a third drug on an existing regimen. No sourced figure exists for this setting.
A.2 Rationale and evidence
What the drug is. Eftilagimod alfa is not an antibody. It is a manufactured, dimeric copy of the outer part of the human LAG-3 protein, joined to an antibody tail so that it stays in the blood. It is given as a 30 mg injection under the skin every two weeks [2] [29].
How it works. On a T cell, LAG-3 is a brake. That is why most companies make antibodies that block it; one, relatlimab, is approved with nivolumab in melanoma [27]. Efti works from the other side. As a free-floating protein it binds MHC class II on antigen-presenting cells and switches those cells on. They mature, show tumour fragments to T cells, and recruit CD4 and CD8 T cells. Blood levels of interferon-gamma and CXCL10 rise [2] [30]. According to PubMed.
Why this combination in this disease. Soft tissue sarcomas are “immune-cold”: they carry few mutations and attract few T cells. Radiotherapy kills tumour cells and releases their contents. Efti switches on the cells that pick that material up. Pembrolizumab then removes the PD-1 brake from the T cells that arrive [3] [31].

Source(s): Atkinson et al. 2020 [2]; Forster et al. 2024 [30]; CT.gov NCT06128863 [3]; Immutep strategy release 2026-09-11 for the manufacturing finding [9]
How well the target is validated. The pharmacology repeats across trials. In a pooled analysis of five trials, lymphocyte counts rose on efti and the patients whose counts rose lived longer [24]. That is a retrospective association, not proof. The one properly controlled test, TACTI-004 in lung cancer (756 patients planned, randomised, double-blind), was stopped for futility on 2026-03-13 [11] [15]. In July the company said efti produced “a markedly different immune activation profile” in TACTI-004 than in earlier studies [32]. On 2026-09-11 it gave a reason: efti made at 2,000 L scale, used only in TACTI-004, differs from the 200 L product used in earlier positive trials, for example in N-glycan structure [9]. That is a hypothesis under test, not a proven cause. Human genetics gives no support: Open Targets finds no genetic association between LAG3 and soft tissue sarcoma [26].
The exact scientific step the next readout must prove. None, in efficacy terms. The primary endpoint was met and announced on 2025-05-27, presented at ESMO 2025 on 2025-10-20 and at CTOS 2025 on 2025-11-13 [33] [8] [12]. The October 2026 catalyst is a health-related quality-of-life analysis of the same 40 patients [6]. It must show that adding nine weeks of injections to five weeks of radiotherapy, before major surgery, did not make patients feel meaningfully worse.
The scientific risk, stated honestly.
- A single-arm trial cannot separate the drug from the backbone. Every patient also got radiotherapy and pembrolizumab, and pembrolizumab plus radiotherapy works on its own [10].
- The endpoint is a surrogate. Hyalinization measures dead tissue, not relapse or survival. The company calls it “an important surrogate marker associated with improved disease-free and overall survival” [5]; no regulator has accepted it in sarcoma.
- The catalyst’s own endpoint is not registered. HRQoL is not among the trial’s one primary and
seven secondary outcome measures, and
other_outcomesis empty [3]. - Product comparability. If the 2026 hypothesis is right, the batch scale used in EFTISARC-NEO matters, and it is not disclosed which scale was used [9].
What ChEMBL does and does not establish. One record, CHEMBL4594557, maximum phase 2: the molecule’s identity and that no approval exists. No selectivity data, because ChEMBL’s bioactivity data are built for small molecules [29]. ChEMBL’s orphan flag reads 0 despite the FDA designation; the field is stale.
Evidence quality
| Criterion | High (7–10) | Medium (4–6) | Low (1–3) | Where to check | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|---|
| Target validation | Human genetic evidence, or a clinical precedent with the same target | Strong preclinical data, indirect human data | Preclinical only, or conflicting data | Open Targets, GWAS Catalog, literature | 3 | Conflicting data: no genetic association [26]; LAG-3 precedent is for blockade, not agonism [27]; the one randomised test failed [11] [VERIFIED — Open Targets, Immutep 2026-03-13] · Medium |
| Mechanism and target engagement | Proof of mechanism in people (PK and PD, receptor occupancy) | A PD signal with an unclear dose relation | No human PD data | Phase 1 data, publications | 6 | Pharmacodynamic rises repeat across trials and 30 mg is dose-selected [2] [30] [5]; but TACTI-004’s product gave a different profile [32] [VERIFIED — PubMed, Immutep 2026-07-13] · Medium |
| Translational biomarkers | A validated PD or selection biomarker with an available assay | An exploratory biomarker | None | Publications, FDA biomarker qualification | 4 | Lymphocyte count and interferon-gamma are exploratory and retrospective [24] [8] [VERIFIED — Immutep releases] · Medium |
| Clinical effect against standard of care | Randomised, clinically meaningful effect | Single-arm or small randomised signal | No signal, or a weak one | Registries, publications, congress data | 4 | Single-arm signal against a historical radiotherapy-only figure, not against today’s pembrolizumab regimen [5] [10] [VERIFIED — FY26 annual report; Lancet 2024] · Medium |
| Consistency and replication | Replicated across trials or subgroups | One trial | Inconsistent | Trial results | 4 | One trial in this indication; across indications, positive single-arm results and a failed Phase 3 [11] [VERIFIED — CT.gov] · Medium |
| Therapeutic window and safety | Wide margin, no class liability | Manageable side effects | Dose-limiting toxicity or a class liability | Toxicology, clinical safety, FAERS, class labels | 8 | No dose-limiting toxicity up to 30 mg; injection-site reactions the main event; no grade 3+ attributed to efti here [2] [8] [22] [VERIFIED — PubMed, Immutep 2025-11-13] · High |
| Data transparency and expert view | Peer-reviewed; supportive named experts (A.2b) | Abstracts only; mixed views | Press releases only; sceptical experts | PubMed, congresses, A.2b | 4 | EFTISARC-NEO exists as congress abstracts and press releases; no paper [23]. The one independent voice in A.2b places efti behind relatlimab on demonstrated efficacy (row Giri et al.); the investigator rows are the sponsoring department [UNVERIFIED — expert view score] · Low |
Endpoints
| Endpoint (full name) | What it measures | Scale / range | Better direction | MCID / note |
|---|---|---|---|---|
| Pathologic response: percent tumour hyalinization/fibrosis (registered primary) | How much of the removed tumour is scar tissue at surgery | 0–100% of the specimen | Higher | No established minimal clinically important difference. ≥35% is conventionally a response; radiotherapy alone gives about 15%. Result: median 51.5% (n=38) [VERIFIED — CT.gov NCT06128863; FY26 annual report] [3] [5] |
| Health-related quality of life (what this catalyst reports) | What patients report about pain, fatigue, function and wellbeing during treatment | Instrument not disclosed; if EORTC QLQ-C30, global health status 0–100 | Higher | Not a registered outcome measure. On the QLQ-C30, about 10 points is conventionally meaningful [VERIFIED — CT.gov, for the absence]; instrument [UNVERIFIED] [3] [6] |
| Disease-free survival (DFS) (registered secondary) | Time from surgery to any recurrence or death | Months | Longer | Follow-up to 2027-04-30. The endpoint that matters for approval [3] |
| Local recurrence-free survival (registered secondary) | Time from surgery to recurrence at the original site | Months | Longer | SARC032’s benefit was mainly in distant, not local, recurrence [3] [10] |
| Distant metastasis-free survival (registered secondary) | Time from surgery to cancer elsewhere in the body | Months | Longer | The endpoint the immune hypothesis predicts [3] |
| Overall survival (registered secondary) | Time from surgery to death from any cause | Months | Longer | Immature [3] |
| Objective response rate, RECIST 1.1 (registered secondary) | Share of tumours shrinking by ≥30% on imaging before surgery | 0–100% | Higher | Reported 19.0%; sarcomas often scar without shrinking [8] |
| Number of participants with adverse events (registered secondary) | Safety, graded on CTCAE v5.0 | Counts by grade | Fewer | No grade 3+ attributed to efti or pembrolizumab [8] |
| Number completing neoadjuvant therapy (registered secondary) | Patients completing treatment and curative surgery per protocol | Count | Higher | Not separately reported [3] |
A.2b Named experts
Panel as of. 2026-10-17.
Investigators
The registry lists no principal investigator or site contacts for NCT06128863, and
search_investigators on “Teterycz” returned no trials. One investigator is now named by a
primary source: the company’s release names Paweł Teterycz as the first author of the ESMO 2026
abstract [6]. The two other names are carried from the 2026-08-19 sweep on inference from the
sponsoring department’s authorship.
| Name | Role / affiliation | Trial (NCT) | Conflicts (party, kind, disclosed in, as of) | Conflicts checked (source, date) | Source | Tag |
|---|---|---|---|---|---|---|
| Paweł Teterycz | First author of the ESMO 2026 EFTISARC-NEO HRQoL abstract; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw | NCT06128863 | Sponsor (Immutep), institutional: his department sponsors a trial Immutep supplies drug for. Disclosed in: Immutep release, 2026-07-24 | PubMed search_articles “Teterycz P[Author] AND sarcoma”, 56 hits, metadata for three, 2026-10-17: affiliations only, no conflict-of-interest field. CT.gov search_investigators “Teterycz”, 2026-10-17: no trials. No NIH RePORTER search (outside its scope) | Immutep release 2026-07-24 [6]; PubMed, Czarnecka et al. 2026 [34] | [VERIFIED — Immutep release 2026-07-24, for the authorship] |
| Piotr Rutkowski | Head of the sponsoring department, Warsaw. Not confirmed as an investigator by the registry | NCT06128863 (institution only) | Sponsor (Immutep), institutional, as above. Disclosed in: author affiliation, Wiśniewska et al. 2026, as of 2026-01-24 | PubMed PMID 41587647, 2026-08-19 and 2026-10-17: no conflict field. CT.gov search_investigators on the institution, 2026-08-19: none on this trial | PubMed [31] | [UNVERIFIED — inferred from institutional authorship] |
| Paweł Sobczuk | Sponsoring department, Warsaw, and Vall d’Hebron Institute of Oncology, Barcelona. Corresponding author of a LAG-3 review. Not confirmed as an investigator | NCT06128863 (institution only) | Sponsor (Immutep), institutional, as above. Disclosed in: Wiśniewska et al. 2026, as of 2026-01-24 | PubMed PMID 41587647, 2026-10-17: no conflict field | PubMed [31] | [UNVERIFIED — inferred from institutional authorship] |
Independent voices
One voice was found, and it comments on the LAG-3 drug class rather than on this endpoint. Nobody outside the sponsoring institution was found commenting on neoadjuvant pathologic response or quality of life with this combination.
| Name | Affiliation | View (close enough to quote) | As of | Conflicts checked (source, date) | Source | Tag |
|---|---|---|---|---|---|---|
| Vinay K. Giri, David F. McDermott and Jacob Zaemes | Division of Medical Oncology, Harvard Medical School / Beth Israel Deaconess Medical Center, Boston | ”To date, the most significant demonstration of efficacy in targeting LAG-3 has been the use of relatlimab with the PD-1 inhibitor nivolumab in the treatment of advanced melanoma.” That places efti below the blocking antibody on demonstrated efficacy, and says nothing about sarcoma. | 2025-05-15 | PubMed PMID 40344213, 2026-08-19 and 2026-10-17: affiliations, no conflict field; none certified absent. No NIH RePORTER search | PubMed, Cancer 2025 [27] | [VERIFIED — PubMed get_article_metadata, 2026-10-17] |
Judgement
| Endpoint supported | Basis (one or two sentences) | Tag |
|---|---|---|
| UNKNOWN | No independent voice has commented on either endpoint that matters: hyalinization or quality of life. The one voice found comments on the LAG-3 class, and the trial has no publication to attract commentary. | [UNVERIFIED — judgement] |
Dissent
Empty. Endpoint supported is UNKNOWN, so there is no claimed support for anyone to contest.
| Name | View (close enough to quote) | Source |
|---|
A.3 Go / No-Go questions
The next decision is go to Phase 3: the registration-directed trial targeted for 2H CY2027 [9].
| # | Question | Go to Phase 2 | Go to Phase 3 | Filing | Answer (tagged, at most three points) [n] | Rating | Confidence |
|---|---|---|---|---|---|---|---|
| Target | |||||||
| T1 | Is proof of mechanism or principle established in people (target engagement, PD) with this candidate? | ● | ● | Pharmacodynamic rises repeat across trials [2] [30]; in this trial interferon-gamma and CXCL9/10 rose and tracked response [5]. But TACTI-004’s product behaved differently [32] [VERIFIED — PubMed, Immutep releases] | amber | M | |
| T2 | If the early population differs from the intended population, how is the evidence translated? | ● | ● | It does not differ: EFTISARC-NEO enrolled the intended population [3] [VERIFIED — CT.gov] | green | M | |
| T3 | Is there a rationale for combinations, and is it pursued? | ● | ● | ● | Yes: radiotherapy for antigen, efti for presentation, pembrolizumab to release the brake; tested together [3] [VERIFIED — CT.gov] | green | H |
| Dose and drug | |||||||
| D1 | Is the exposure–response relationship and the therapeutic window defined for the intended regimen and route? | ● | ● | ● | 30 mg selected through Project Optimus [5]; no exposure–response model published, and none in sarcoma [VERIFIED — FY26 annual report] | amber | M |
| D2 | Is the dose and regimen compatible with the clinical and non-clinical safety data? | ● | ● | ● | Yes. No dose-limiting toxicity at 30 mg across several hundred patients [2] [22] [VERIFIED — PubMed] | green | H |
| D3 | Does the formulation deliver therapeutic exposure, and is it commercially viable (the final formulation for Phase 3)? | ● | ● | ● | Open. 2,000 L product differs from 200 L product in N-glycan structure; a new 200 L run is contracted [9]. Which product EFTISARC-NEO used is not disclosed [VERIFIED — Immutep 2026-09-11] | red | M |
| D4 | Are intrinsic and extrinsic factors (organ impairment, drug interactions, ethnicity, body weight) characterised? | ● | ● | No public record as of 2026-10-17 [23] [UNVERIFIED] | amber | L | |
| Patient and design | |||||||
| P1 | Are the design and endpoints accepted by the FDA and EMA, clinically meaningful, competitive, and relevant for HTA bodies (B.3)? | ● | ● | ● | No design disclosed; the primary endpoint is an unvalidated surrogate; no agency agreement announced [9] [VERIFIED — Immutep 2026-09-11] | red | M |
| P2 | What is the rationale for the population; is a selection biomarker validated, with a companion diagnostic plan? | ● | ● | ● | Strong rationale: large, deep, high-grade tumours relapse most [10]. No biomarker needed or proposed [3] [VERIFIED — Lancet 2024; CT.gov] | green | M |
| P3 | What is the probability of success of the next trial (effect-size assumptions, statistical power, trial simulation or assurance)? | ● | ● | Not computable: no design, effect size or power is disclosed [UNVERIFIED] | amber | L | |
| P4 | Has proof of concept with a positive benefit–risk balance been shown in the intended population? | ● | ● | Proof of concept on a surrogate, against a historical control, in 38 patients [5] [VERIFIED — FY26 annual report] | amber | M | |
| Benefit–risk | |||||||
| R1 | Is the safety database adequate for the indication (exposure, duration); are class effects or a REMS expected? | ● | ● | Several hundred patients on efti overall, 40 in this setting; no class effect expected [2] [22] [VERIFIED — PubMed] | amber | M | |
| R2 | Is the overall benefit–risk balance favourable against the current standard of care? | ● | ● | Not established against pembrolizumab plus radiotherapy [10] [UNVERIFIED] | amber | L |
Clinical data and design: 4.0 (direct). Basis: one single-arm trial of 38 evaluable patients met a surrogate endpoint (P4); D3 and P1 are red; no comparison against the current regimen exists (R2). · confidence Medium
A.4 Regulatory pathway
| Topic | Questions | Answer (tagged) [n] | Where to look |
|---|---|---|---|
| Pathway | Which route: NDA or BLA, 505(b)(2), EU centralised MAA, conditional authorisation or accelerated approval? Is a confirmatory trial required, and is it feasible? | A full BLA in the US and a centralised MAA in the EU would be needed. An accelerated approval on hyalinization has no precedent. A confirmatory DFS trial would take years [UNVERIFIED — judgement] | FDA guidance, EMA procedural guidance |
| Designations | Breakthrough Therapy, Fast Track, RMAT, Orphan Drug, priority review voucher (FDA); PRIME, orphan (EMA); Sakigake, orphan (PMDA): granted, or realistic? | FDA Orphan Drug Designation in STS, 2026-04-15 [4]. Fast Track exists only in head and neck cancer and lung cancer [9]. No EU or Japanese designation found in the filings [VERIFIED — Immutep releases] | Company filings, FDA and EMA registers |
| Agency alignment | End-of-Phase-2 meeting, scientific advice, SPA, parallel EMA and HTA advice: was the pivotal design agreed? | No. The company cites “prior interactions” with the FDA in general terms; no meeting on an STS design is announced [9] [VERIFIED — Immutep 2026-09-11] | Company disclosures, EMA scientific advice |
| Precedent | Have drugs been approved on the same endpoint and design in this indication? Any recent rejections in the class? | No drug is approved before surgery in STS. Pembrolizumab’s SARC032 use is off-label: its label has no sarcoma indication [28]. Olaratumab, approved in advanced STS on a randomised Phase 2, was withdrawn in 2019 after its Phase 3 failed [35] [VERIFIED — DailyMed; G-BA] | Drugs@FDA, EPARs, PMDA review reports |
| Review risk | Likelihood of an advisory committee; safety signals; manufacturing inspection; co-approval of a diagnostic; post-marketing requirements | Manufacturing comparability (D3) would be the central review risk. No diagnostic needed [UNVERIFIED — judgement] | AdComm materials, CRL disclosures |
Regulatory pathway: 4.0 (direct). Basis: an orphan designation is held, but there is no agreed design or endpoint, no approval precedent for the endpoint, and an open manufacturing question. · confidence Medium
Designations.
- FDA Orphan Drug Designation, soft tissue sarcoma, granted 2026-04-15. It gives seven years of US market exclusivity for that indication if the drug is approved, fee exemptions and tax credits. It makes no efficacy judgement [4].
- No Fast Track, Breakthrough Therapy or Special Protocol Assessment in soft tissue sarcoma. Efti’s Fast Track designations are in head and neck cancer and lung cancer [9].
- No EU orphan designation was found in the company’s filings as of 2026-10-17. The EU register
itself was not searched
[UNVERIFIED].
A.5 Clinical operations

Source(s): CT.gov NCT06128863 [3]; SARC032 Lancet 2024 [10]; Immutep releases and filings [4] [9] [11] [33] [36]
Milestone dates. First patient in 2023-07-17. Registry primary completion 2025-04-30; topline announced 2025-05-27, 27 days later. Database lock not disclosed. Study completion, covering the 24-month follow-up, 2027-04-30 [3] [12].
Trials
| Trial | Sponsor / whose drug | Design (arms, blinding, n) | Population | Status / key result | Link |
|---|---|---|---|---|---|
| EFTISARC-NEO | Maria Skłodowska-Curie National Research Institute of Oncology, with Immutep S.A.S. as collaborator; funded mainly by a €1.5M Polish government grant (about A$2.2M). Efti is Immutep’s; pembrolizumab is Merck’s | Phase 2, single-arm, single-stage, open-label, one site, n=40 | Adults with resectable, non-metastatic, deep, grade 2–3 STS of limbs, girdles or superficial trunk; >5 cm or recurrent | Primary endpoint met: median 51.5% hyalinization (n=38) against a 35% target. Active, not recruiting. No results posted | NCT06128863 [3] [5] |
| SU2C-SARC032 (competitor precedent) | Academic, funded by Stand Up to Cancer and Merck. Pembrolizumab is Merck’s | Randomised, open-label, two arms, 143 randomised (127 analysed) | Stage III undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma of the limb or limb girdle | Primary endpoint met: DFS hazard ratio 0.61 (90% CI 0.39–0.96); 2-year DFS 67% against 52% | NCT03092323 [10] [14] |
| TACTI-004 | Immutep S.A.S. | Phase 3, randomised, double-blind, placebo-controlled, 756 planned | First-line advanced lung cancer | Stopped for futility 2026-03-13 at an interim of about 170 patients; registry still shows “active, not recruiting” | NCT06726265 [11] [15] [37] |
| AIPAC | Immutep S.A.S. | Phase 2b, randomised, double-blind, placebo-controlled, n=242 (226 treated) | HR+ HER2-negative metastatic breast cancer on paclitaxel | PFS not met (7.3 months both arms). Quality of life sustained on efti, deteriorated on placebo | NCT02614833 [22] [16] |
| TACTI-002 | Immutep S.A.S. | Phase 2, open-label, single-arm parts, n=187 | Lung cancer; head and neck cancer | Second-line head and neck: response rate 29.7%; second-line PD-(L)1-refractory lung: 8.3% | NCT03625323 [30] [17] [38] |
| TACTI-003 | Immutep S.A.S. | Phase 2b, randomised, open-label, n=171 | First-line head and neck cancer | Completed 2024-03. The basis of the 2026 head-and-neck focus | NCT04811027 [18] |
| AIPAC-003 | Immutep S.A.S. | Phase 2/3, randomised after open-label dose optimisation, n=72 | HER2-negative/low metastatic breast cancer | Terminated; closed 2026-06-30 | NCT05747794 [19] |
| TACTI-mel | Immutep Australia | Phase 1, open-label, dose escalation, n=24 | Metastatic melanoma | Response rate 33% (part A), 50% (part B) | NCT02676869 [2] [20] |
Pivotal programme
| Trial | Setting | Design / comparator | Key result [n] | Use |
|---|---|---|---|---|
| None yet | Neoadjuvant STS | Not designed. Start targeted 2H CY2027, subject to design, regulators, manufacturing, partnering and resources | — [9] | Would support a US BLA and EU MAA |
| EFTISARC-NEO | Neoadjuvant STS | Single-arm; historical control | Median hyalinization 51.5% [5] | Proof of concept and the basis of the orphan designation; not pivotal |
Effect by trial
Not applicable — no randomised trial of efti in soft tissue sarcoma exists.
| Trial | Endpoint | Effect (hazard ratio or other, named) | 95% confidence interval | n | Source |
|---|
Operational parameters
| Parameter | High (7–10) | Medium (4–6) | Low (1–3) | Where to check | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|---|
| Recruitment feasibility | Sites and countries adequate for the disease’s prevalence; enrolment on or ahead of benchmark | Adequate, with competing trials for the same patients | Rare population, few sites, enrolment delays | ClinicalTrials.gov, EU CTIS | 3 | One site, one country. A randomised successor would need many sites; SARC032 needed 20 institutions and six years to randomise 143 [3] [10] [VERIFIED — CT.gov; Lancet] · Medium |
| Endpoint acceptance | Regulatory precedent in FDA or EMA guidance | Novel endpoint with documented agency agreement | Unvalidated surrogate | FDA and EMA guidance, EPARs | 3 | Hyalinization is unvalidated; DFS would need a randomised trial [3] [VERIFIED — CT.gov] · Medium |
| Design robustness | Randomised, controlled, agreed with the agencies (SPA) | Adaptive or seamless, with a pre-specified interim | Single-arm without a robust external control | Protocol, SPA, scientific advice | 2 | Single-arm, historical control only [3] [VERIFIED — CT.gov] · High |
| Execution track record | Sponsor met its prior milestones | Minor delays | Repeated delays, CRO or site problems | Company history, 8-K filings, ../company.md C.1a | 6 | EFTISARC-NEO met every date with zero slips; the company met its TACTI-004 and Nasdaq dates. Against that, a Phase 3 failed on what the company now attributes to a product difference (../company.md C.1a) [VERIFIED — Immutep filings] · Medium |
Resourcing sufficiency. For this catalyst, sufficient and nearly free: the trial is run and
funded by the Warsaw institute, and what remains is an ePoster [5]. For the next step the answer
inverts. The registration-directed trial is targeted for 2H CY2027 “subject to … partnering and
resources” [9]. The company holds about A$61M net of debt-like items at 2026-06-30, guides cash
“well into the first half of CY2028”, and has cut headcount (../company.md C.3) [39].
A multi-site randomised sarcoma trial would consume most of that. B.4c says more.
A.6 Probability of success
Base rate. baseRate({ phase: "phase2", area: "oncology", modality: "other" }) in
lib/success-rates.mjs, run in node on 2026-10-17. Modality other has no category in the table,
so the lookup falls back to the area level.
Base rate: 24.6% to the next phase · 10.8% to approval · source BIO 2021, Figure 2, p. 7
(Oncology) · fallback level area · Wong 2019 32.7% to the next phase and 11.6% to approval
[WEB ESTIMATE — BIO/Informa/QLS 2021] [7]
Adjustments
| Factor | Direction (up / down) | Evidence [n] | Tag |
|---|---|---|---|
| Biomarker-selected population | — | not applicable: no selection | — |
| Human genetic support for the target | down | No genetic association between LAG3 and soft tissue sarcoma [26] | [VERIFIED — Open Targets, 2026-10-17] |
| Rare disease or orphan designation | up | FDA Orphan Drug Designation, 2026-04-15 [4] | [VERIFIED — Immutep release] |
| Randomised Phase 2 with a meaningful effect | down | Single-arm only; the comparison is historical [3] | [VERIFIED — CT.gov] |
| First-in-class, novel endpoint, or prior failures in the class | down | First-in-class agonist; TACTI-004 stopped for futility; AIPAC missed PFS; AIPAC-003 terminated [11] [22] [19] | [VERIFIED — Immutep, PubMed, CT.gov] |
| Other, named: met primary endpoint by a wide margin | up | 51.5% median against a 35% target [5] | [VERIFIED — FY26 annual report] |
| Other, named: no designed or funded next trial | down | Start targeted 2H CY2027, subject to resources and partnering [9] | [VERIFIED — Immutep 2026-09-11] |
| Other, named: manufacturing comparability open | down | N-glycan difference between production scales; new 200 L run contracted [9] | [VERIFIED — Immutep 2026-09-11] |
Result
| Low | Base | High | Basis | |
|---|---|---|---|---|
| To the next phase | 10% | 20% | 35% | Below the 24.6% base rate: five downward factors against two upward. The low edge allows for the trial never being funded [UNVERIFIED — modelled] |
| To approval | 2% | 5% | 10% | Below the 10.8% base rate for the same reasons, plus an unvalidated endpoint [UNVERIFIED — modelled] |
These figures concern the program’s path to Phase 3 and approval. The October catalyst asks a narrower question, and the outcome call in Locked prediction explains its distance from the base rate.
A.7 Modality
- Modality:
other. An Fc fusion protein: the outer part of human LAG-3 fused to an IgG1 antibody tail, made in cultured cells and injected under the skin [2] [29]. - Manufacturing is assessed in M below. Its CMC score feeds the Operations and CMC domain.
M. Manufacturing (CMC)
Short form: the program is at Phase 2, so M.1 and the M.6 score are written, and M.2 to M.5 are
not applicable (01-rules.md rule 44). The manufacturing tier of the sweep does not apply yet.
M.1 Product and process
| Element | Describe | This asset [n] |
|---|---|---|
| Molecule or construct | For an antibody: isotype and expression system. For a conjugate: linker chemistry, payload class, conjugation site, DAR and its distribution. For a gene therapy: vector or capsid. For an RNA drug: the lipid nanoparticle. For a radioligand: the isotope | A dimeric fusion of the LAG-3 extracellular domains with an IgG1 Fc tail; a glycoprotein made in cultured mammalian cells. The 2026 root cause analysis found N-glycan differences between 2,000 L and 200 L batches [2] [9] [VERIFIED — Immutep 2026-09-11] |
| Drug substance steps | Upstream (growing the cells), downstream (purifying the product), payload and linker synthesis, conjugation, purification; in-house or CDMO for each step | Made by a third-party contract manufacturer; not named in the FY26 annual report. Ten GMP batches were made at 200 L; TACTI-004 used only 2,000 L material; a new 200 L run is contracted [5] [9] [VERIFIED — FY26 report; 2026-09-11] |
| Drug product | Formulation (liquid or freeze-dried), presentation, device, stability and shelf life, refrigerated transport (cold chain) | 30 mg subcutaneous presentation used across the programme. Shelf life and presentation not disclosed [UNVERIFIED] [2] |
| Analytics | The critical quality attributes (such as DAR, free payload, aggregates, potency assay, vector genomes) and the release and characterisation methods | A proprietary MHC class II binding assay used as a GMP quality-control step, patented in FY26 [5]. The assay did not flag the glycan difference before TACTI-004 [VERIFIED — FY26 report; inference from the timing] |
| Companion diagnostic | The assay, its partner, and the timing of its co-approval (A.4) | None needed [3] |
M.2 Challenges by process step
Not applicable — short form before Phase 3.
| Process step | Typical challenges | Status and readiness (tagged) [n] | Rating |
|---|
M.3 Regulatory CMC track record
Not applicable — short form before Phase 3.
| Item | What to record | Where to find it | Finding (tagged) [n] |
|---|
M.4 Network and capacity
Not applicable — short form before Phase 3. The company’s manufacturing network is in
../company.md C.1a.
| Topic | Finding (tagged) [n] |
|---|
M.5 Modality questions
Not applicable — short form before Phase 3.
| Modality | Key CMC and technology questions | Answer for this asset (tagged) [n] |
|---|
M.6 CMC score and top risks
Scored from M.1 and the public record, as the short form allows.
| Criterion | High (7–10) | Medium (4–6) | Low (1–3) | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|
| Process robustness and CQAs | Validated commercial process; well-defined CQAs | Process changes pending; comparability needed | Quality problems recognised late | 2 | A structural difference between scales was found only after a Phase 3 failed [9] [VERIFIED — Immutep 2026-09-11] · Medium |
| Regulatory CMC record | No CMC-related CRL or Form 483 issue | Minor observations, resolved | A CMC CRL, a warning letter or a refusal | 6 | No public record of a CRL or Form 483, but the product has never been filed or inspected for approval [UNVERIFIED — absence] · Low |
| Capacity and supply | Capacity matched to demand; dual sourcing | Constrained, or a single site | Shortages, or a major over-capacity write-down | 4 | One contract manufacturer; the larger scale is under question; A$6.46M of its invoices on deferred terms [5] [VERIFIED — FY26 report note 18] · Medium |
| Cost of goods | Compatible with the price corridor | Margin pressure | COGS threatens viability | 6 | A 30 mg dose is small for a biologic; the move back to 200 L may raise unit cost; no figure disclosed [UNVERIFIED] · Low |
CMC score: 4.5 (mean of the four, from lib/scorecard.mjs)
Top-3 CMC risks. 1. The 200 L product may not restore the activity seen in earlier trials, or the regulator may require comparability work before a registrational trial [9]. 2. Which batch scale EFTISARC-NEO used is undisclosed, so its result may not transfer to future product [9]. 3. A single contract manufacturer, partly paid on deferred terms [5].
B. Commercial value
B.1 Treatment today and competitors
Treatment algorithm. For a large, deep, high-grade, resectable sarcoma of a limb or the trunk:
- Imaging, biopsy and grading. Small, superficial or low-grade tumours go straight to surgery.
- Radiotherapy before surgery, about five weeks. This is long-standing practice [10].
- Chemotherapy before surgery for selected subtypes; contested and not universal
[UNVERIFIED]. - Pembrolizumab added to radiotherapy for selected subtypes, after SARC032 improved disease-free survival [10].
- Wide surgical removal, five to six weeks after radiotherapy.
- If the cancer returns, usually at a distant site, doxorubicin-based treatment and later lines.
Where efti would fit: step 4, as a third drug. It would replace nothing. It would sit on top of the regimen whose benefit was shown without it.
Competitors
| Competitor (drug, company) | Stage | Key data [n] | Note (indirect comparison) |
|---|---|---|---|
| Pembrolizumab with radiotherapy (Merck; academic trial) | Randomised trial complete, published; not FDA-approved in sarcoma | 2-year DFS 67% against 52%; HR 0.61; grade 3+ adverse events 56% against 31% [10] | Indirect against EFTISARC-NEO: different endpoint (DFS against hyalinization), narrower subtypes, different follow-up |
| Radiotherapy then surgery (standard care) | Standard | 2-year DFS 52% in SARC032’s control arm; median hyalinization about 15% historically [10] [5] | The historical 15% is not from a concurrent control |
| Other LAG-3 drugs (relatlimab and others) | Approved in melanoma only | Not tested in sarcoma [27] | They block LAG-3; efti activates the MHC class II side |
Competitive position
| Metric | High value (7–10) | Medium value (4–6) | Low value (1–3) | Where to check | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|---|
| Mechanism differentiation | First-in-class, or clearly best-in-class | Next-generation improvement | Me-too | Publications, the competitor list above | 8 | The only MHC class II agonist in clinical development [27] [40] [VERIFIED — PubMed] · High |
| Timing against competitors | More than 12 months ahead of the nearest competitor | Within 6 to 12 months | Lagging by more than 12 months | ClinicalTrials.gov | 2 | Pembrolizumab plus radiotherapy published randomised data in 2024; efti’s next trial would start in 2H CY2027 at the earliest [10] [9] [VERIFIED — Lancet; Immutep] · High |
| Clinical data against competitors | Superior efficacy, safety or convenience (B.1a) | Comparable | Inferior | Publications, congress data | 5 | Safety looks better in a cross-trial view; efficacy cannot be compared (no DFS) [10] [8] [UNVERIFIED — indirect] · Low |
| IP and exclusivity | 10 years or more after launch (composition of matter) | 5 to 10 years, or method of use only | Under 5 years, or pending only | Orange Book, Purple Book, patent databases | 5 | Method-of-use patent on efti with a PD-1 inhibitor to 2036 (carried from the 2026-08-19 sweep); acquired composition patents amortised over their legal life; orphan exclusivity of 7 years on approval; biologic exclusivity if approved [4] [5]. The 2036 patent [UNVERIFIED — carried from the 2026-08-19 sweep, not re-read]; the rest [VERIFIED — FY26 report; Immutep] · Medium |
Strategic insight. No sourced first-mover observation for neoadjuvant sarcoma exists. The
illustrative oncology figure is roughly 3.2 times the peak-sales potential and 1.8 times the
development risk for a first mover with a novel mechanism [UNVERIFIED — illustrative]. Efti is
first in its mechanism and last in its setting. It wins only if it is the best way to make an
already-working immune regimen work better. The investment case rests on one fact: that the 51.5%
median hyalinization reflects something efti added, not what pembrolizumab plus radiotherapy does
alone. Nothing yet separates the two.
B.1a Efficacy against side effects
Every comparison here is indirect (01-rules.md rule 17). The patients, subtypes, follow-up and
side-effect definitions differ between trials. Efti is not placed on the chart: EFTISARC-NEO has
reported no disease-free survival, so there is no point on the shared efficacy axis. Its data are
in the table.

Source(s): SU2C-SARC032 [10]. Scaling: x = 2-year DFS as a fraction (0.52 and 0.67); y = 1 minus the grade 3+ adverse-event rate (0.69 and 0.44). Indirect comparison across trials (rule 17).
| Indication | Regimen (trial) | Efficacy (endpoint, value) | Grade 3 or higher adverse events (%) | Adverse event definition (any cause, treatment-emergent or treatment-related) | Source |
|---|---|---|---|---|---|
| Resectable STS | Radiotherapy then surgery (SARC032 control) | 2-year DFS 52% | 31% | As reported in the Lancet abstract, grade 3 or higher adverse events | [10] |
| Resectable STS | Pembrolizumab with radiotherapy then surgery and adjuvant pembrolizumab (SARC032) | 2-year DFS 67%; HR 0.61 | 56% | As above | [10] |
| Resectable STS | Efti with pembrolizumab and radiotherapy, early data (EFTISARC-NEO, single-arm) | Median hyalinization 51.5%; DFS not reported | Not disclosed (no grade 3+ attributed to efti or pembrolizumab) | Treatment-related only | [5] [8] |
B.2 Addressable market
| Component | How it is estimated | Assessment guide | This asset (tagged) | Source [n] |
|---|---|---|---|---|
| Drug-treated patients | Prevalence or incidence × diagnosis rate × treatment rate × eligible share | More than 100,000 (US, EU5, Japan) is a premium threshold for a common disease; judge an orphan market relative to its area | About 5,000–7,000 patients a year in the US and EU5, carried from the 2026-08-19 build: about 13,000 US STS cases a year × 60% localised × about half in limbs or trunk × half to 60% grade 2–3 and >5 cm, and the same fractions on about 23,400 EU cases. Each fraction after the first is an assumption | [WEB ESTIMATE — SEER and RARECARE via web search, 2026-08-19]; fractions [UNVERIFIED — modelled] |
| Exclusivity | Patent term + extensions (PTE, SPC) + regulatory, orphan or paediatric exclusivity | Years of exclusivity after launch; the generic or biosimilar entry date | Orphan exclusivity 7 years from US approval; combination patent to 2036; US biologic exclusivity of 12 years if approved as a new biologic. On a 2033 launch, about 7 to 12 years | [4] [5] [UNVERIFIED — modelled on an assumed 2033 approval] |
| Reimbursement precedent | Approvals and payer decisions in two or more major markets | Positive NICE or CADTH guidance for a drug like this one | None for efti. Analogues: olaratumab (advanced STS) recommended within the Cancer Drugs Fund by NICE in 2017, and later withdrawn [41] | [35] [41] |
| Price corridor | Comparator and analogue prices; a value-based price | Worked out in B.3 | US$30,000–80,000 per nine-week course, modelled (B.4a) | [UNVERIFIED — modelled] |
| Patient and system impact | Hospitalisations, caregiver burden, HRQoL | The size of the effect and the evidence for it | The one row this catalyst speaks to: whether nine weeks of injections around radiotherapy preserve quality of life | [6] |
B.3 Payers and price
Per market
| Market | In scope? | Expected outcome | Price implication | Key risk | Source [n] |
|---|---|---|---|---|---|
| United States: ICER benchmark; Medicare negotiation exposure (IRA timing, orphan exclusion) | Always | No ICER assessment exists for this setting. As an orphan-only biologic, efti would be excluded from Medicare negotiation while all its approved uses stay orphan; pembrolizumab was reportedly not selected for 2028 because of the 2025 orphan-exclusion change | No near-term negotiation pressure | Payers may restrict an add-on with single-arm data | [42] [43] [44] |
| EU joint clinical assessment (JCA) | Yes | A JCA would apply to an EU filing (mandatory for new oncology medicines since January 2025). Its comparator would be pembrolizumab plus radiotherapy or radiotherapy alone | Weak relative-effect evidence without a randomised trial | A PICO built around a randomised comparator | [45] |
| Germany: G-BA and IQWiG (AMNOG) | Yes | Orphan benefit deemed while under the €30M revenue limit; quantification needs comparative data | Price capped near the comparator without proven added benefit | The olaratumab precedent: benefit deemed in 2017, decision rescinded in 2020 after withdrawal | [35] |
| UK: NICE | Yes | A positive recommendation would need DFS against the comparator; managed access is possible | Cost per QALY within £25,000–35,000 [UNVERIFIED — illustrative] | TA185 recommended trabectedin only with a cost cap | [41] [46] |
| Japan: Chuikyo | Retained, not modelled | Not assessed: no plan for Japan is announced | — | — | [47] |
Questions
| Question | Answer (tagged) [n] |
|---|---|
| Comparator: does the pivotal trial compare against what payers require (the G-BA’s appropriate comparator, the NICE scope, the JCA’s PICO, the US standard of care)? If not, is a credible bridge planned, such as an indirect comparison or an external control? | No. EFTISARC-NEO has no comparator. No bridge is planned [VERIFIED — CT.gov] [3] |
| Endpoints and certainty: patient-relevant endpoints (mortality, morbidity, quality of life, safety) or surrogates? Will payers discount the design (single-arm, crossover, immature data)? | Surrogate (hyalinization) from a single-arm trial; payers will discount it heavily. The HRQoL data are patient-relevant but unregistered [VERIFIED — CT.gov] [3] |
| Supplementary evidence: quality-of-life data (EQ-5D), early payer advice (EU joint scientific consultation, G-BA, NICE), real-world or natural-history data, an early cost-effectiveness model? | HRQoL data exist (this catalyst); the instrument is undisclosed, and EQ-5D is not known to be collected. No payer advice is announced [UNVERIFIED] [6] |
| Value against price: a realistic G-BA added-benefit category; cost per QALY against the NICE threshold; the ICER price benchmark. Do they support the target price against the comparator? | Not assessable without comparative efficacy [UNVERIFIED] |
| Access conditions: likely restriction to sub-populations, managed access or confidential discounts, post-launch data obligations? | Likely restriction to subtypes where pembrolizumab is used, managed access, and confirmatory DFS obligations [UNVERIFIED — judgement] |
| US comparator annual cost (list price), the ICER benchmark, and the Medicare negotiation timing for this drug (small molecule 7 years, biologic 11 years after approval; orphan exclusion) | Pembrolizumab’s US list price was not read this sweep. No ICER benchmark. Efti would be a biologic (11 years), likely excluded while orphan-only [44] [WEB ESTIMATE — Milliman, secondary, read 2026-10-17] |
Market access criteria
| Criterion | High (7–10) | Medium (4–6) | Low (1–3) | Score | Basis (tagged) [n] · confidence |
|---|---|---|---|---|---|
| Comparator alignment | Randomised trial against the payers’ comparator | Robust indirect comparison | Placebo or single-arm only | 2 | Single-arm only [3] [VERIFIED — CT.gov] · High |
| Endpoints and certainty | Hard endpoint, mature, randomised | Surrogate, immature | Unvalidated surrogate, single-arm | 2 | Unvalidated surrogate, single-arm [3] [VERIFIED — CT.gov] · High |
| Supplementary evidence plan | Quality of life (EQ-5D), payer advice, real-world evidence, a cost-effectiveness model | Partial | Not addressed | 4 | HRQoL collected; nothing else known [6] [VERIFIED — Immutep 2026-07-24] · Medium |
| Value for money at the target price | Within the NICE threshold, or at or below the ICER benchmark | Needs a discount | Far above the thresholds | 4 | No price and no comparative effect; an add-on would likely need a discount [UNVERIFIED] · Low |
| Payer precedent | Positive, with a premium price | Restricted or mixed | Rejected, or priced at the comparator | 4 | Mixed: olaratumab’s orphan benefit was deemed and later rescinded; trabectedin recommended with a cost cap [35] [41] [46] [VERIFIED — G-BA, NICE] · Medium |
Market Access Score: 3.2 (mean of the five, from lib/scorecard.mjs)
Payer decisions
| Market | Indication / evidence | Outcome (body’s own words, date) | Main reason | Source [n] |
|---|---|---|---|---|
| Germany | Olaratumab with doxorubicin, advanced STS; randomised Phase 2 | Added benefit deemed proven as an orphan drug (2017-05-18); decision rescinded 2020-01-16 after the EU authorisation was revoked on 2019-07-19 | Orphan rule; then the confirmatory Phase 3 failed | [35] |
| UK | Olaratumab with doxorubicin, advanced STS | Recommended for use within the Cancer Drugs Fund (TA465, 2017-08-09) | Immature survival data | [41] |
| UK | Trabectedin, advanced STS after anthracyclines | Recommended where the manufacturer caps the cost after the fifth cycle (TA185, 2009; updated 2021-02) | Cost-effectiveness | [46] |
| Japan | Trabectedin, STS | Listed on the NHI price list 2015-11-26 | — | [47] |
Two of these four decisions are older than the template’s seven-year window. They are kept because no newer payer decision in soft tissue sarcoma was found, and the olaratumab rescission (2020) is inside the window.
B.4 Valuation and financing
B.4a Peak sales
Built bottom-up for the STS indication only, the US and EU5 only, and conditional on an
approval that is not yet funded. It excludes every other efti indication, all partner territories
and IMP761. Launch is assumed in 2033: a trial starting 2H CY2027 with a DFS endpoint would read out
around 2031 [UNVERIFIED — modelled]. The build is carried from the 2026-08-19 version unchanged,
because nothing in this sweep moved its inputs.
| Scenario | Assumptions (patients × price × share × duration) | Estimate (USD/year at peak) | Basis / tag |
|---|---|---|---|
| Low | 6,000 patients × 10% penetration × US$30,000 per nine-week course × one course | ~US$18M | Use only at high-volume sarcoma centres [UNVERIFIED — modelled; efti has never been priced] |
| Base | 6,000 × 25% × US$50,000 × one course | ~US$75M | Adoption at the referral centres that treat most of this population [UNVERIFIED — modelled] |
| High | 6,000 × 40% × US$80,000 × one course | ~US$192M | Guideline inclusion alongside pembrolizumab [UNVERIFIED — modelled] |
Rejected input, kept as an audit trail. The peak-sales search found one figure: US$79M a year by
2038 for efti across all indications, from a paid model quoted by a trade site [48]. It is not
broken out by indication and is not used. The 2026-08-19 sweep also rejected an “AU$1.30
consensus” target as a stale pre-failure figure (01-rules.md rule 6); that rejection stands.
B.4b Value
| Scenario | eNPV (USD) | Assumptions (discount rate, costs, royalties and milestones, loss of exclusivity, probability of success) | Tag |
|---|---|---|---|
| Low | not computed | The registrational trial’s cost and design are undisclosed | [UNVERIFIED — declined] |
| Base | not computed | As above | [UNVERIFIED — declined] |
| High | not computed | As above | [UNVERIFIED — declined] |
Why no range, kept from the 2026-08-19 version. That version declined because two inputs were unbounded: the probability of approval and the cost to approval. A.6 now bounds the first (2–10%). The second is still undisclosed, and so is whether the company or a partner would bear it. A range built on an invented trial cost would look like analysis and carry none.
B.4c Funding
| Question | Answer (tagged) [n] |
|---|---|
| Capital needed to the next decision point | Essentially nil for this catalyst: the trial is grant-funded and the ePoster is the investigators’ [5] [VERIFIED — FY26 annual report] |
| Capital needed to approval, and the funding plan | A multi-site randomised trial with a DFS endpoint; cost not disclosed. The plan is “subject to … partnering and resources”, and the company is “in preliminary discussions with other parties” [9] [VERIFIED — Immutep 2026-09-11] |
Cash runway against those needs (../company.md C.3) | Runway guided “well into the first half of CY2028” (../company.md C.3). A trial starting 2H CY2027 would begin with about two to three quarters of cash left at the guided rate [UNVERIFIED — derived from guidance] |
Financing need and dilution risk before the next decision (../company.md C.3, dilution history) | High before the 2H CY2027 trial start, low before this catalyst. No equity raised in 24 months. A raise with the ADS at about 0.73 times the cash floor would be very dilutive (../company.md C.3, C.4) [UNVERIFIED — judgement] |
B.4d Launch, partnering, rights and economic share
| Question | Answer (tagged) [n] |
|---|---|
| Launch capability: can the company launch alone, or must it partner? | Must partner. No product has ever been sold and there is no sales force (../company.md C.1a) |
| Partnering history and comparable deal terms | Dr. Reddy’s licence of 2025-12-08: US$20M upfront (US$10M repaid in June 2026), up to US$349.5M in milestones, double-digit royalties. Dr. Reddy’s was consulted on and “is supportive of” the 2026-09-11 focus [1] [5] [9] |
| Commercialisation rights: retained, split, or out-licensed? | US, Europe (incl. the UK) and Japan retained; other territories out-licensed (Dr. Reddy’s; EOC Pharma in Greater China) [1] |
| Economic share | 1.0 for the modelled US and EU5 sales, because those territories are fully retained today. A future launch partner would reduce it; no such deal exists, so 1.0 is the honest figure for an upper bound [VERIFIED — Dr. Reddy's release, for the retained territories] |
Visual 4: scenario chart

Source(s): B.4a assumptions; launch year 2033 and the uptake shape are modelled [UNVERIFIED — modelled] [9]. Lines, from bottom: low, base, high.
C. Risk
Framing questions
- Does the development plan support the target product profile claims (A.1)? Not yet. The profile claims an effect on top of pembrolizumab plus radiotherapy. Only a randomised trial against that backbone can support it, and that trial is a 2H CY2027 target, not a plan.
- Would the identified risks change the target product profile? Yes, two of them. The backbone confound attacks the efficacy row. The manufacturing finding attacks the dose and formulation row: the product in a future trial may not be the product that produced 51.5%.
- If a risk cannot be mitigated, is the asset still differentiated from competitors? On mechanism, yes: it stays the only MHC class II agonist. Without controlled efficacy that is a scientific distinction, not a commercial one.
| Risk group | Covers | Time / quality / cost risk | Likelihood | Impact | Mitigation | Source [n] |
|---|---|---|---|---|---|---|
| Science and clinical | Research, biomarker, clinical pharmacology, clinical efficacy, drug safety | Quality: the effect may belong to the backbone; TACTI-004 failed. Time: DFS matures from 2027 | high | high | A randomised trial against pembrolizumab plus radiotherapy. Safety is the strongest row: no near-veto signal | [10] [11] [8] |
| Non-clinical | DMPK, safety pharmacology, toxicology | No signal in several hundred patients | low | low | None needed | [2] [22] |
| Regulatory | Pathway, endpoints, review, post-marketing requirements | Quality: no agreed endpoint; hyalinization has no precedent. Time: agency meetings not yet held | medium | high | FDA interaction on a DFS design before 2H CY2027 | [9] |
| CMC and supply | Process, scale-up, comparability, capacity, diagnostics (from M) | Quality and time: 2,000 L product differs from 200 L product; a comparability programme may be needed. Treated as a potential near-veto until the root cause closes | high | high | New 200 L run contracted; root cause analysis ongoing | [9] |
| IP and legal | Patents, freedom to operate, litigation, licences | Method-of-use protection only; three investor-notice releases by a law firm after TACTI-004, no filed complaint found | medium | medium | Orphan and biologic exclusivity if approved | [5] |
| Access and commercial | Evidence and value, payers, pricing, competition | Quality: single-arm surrogate data; cost: an add-on price on an expensive backbone | high | medium | HRQoL data (this catalyst); a randomised trial | [35] [41] |
| Execution and financing | Project management, clinical operations, funding, partners | Cost and time: the next trial is unfunded; runway to H1 CY2028; ADS at 0.73 times the cash floor | high | high | Partner discussions; Dr. Reddy’s support; cost cuts | [5] [9] |
Risk profile: 3.0 (direct, 10 = low risk). Basis: three groups sit at high likelihood and high impact (science and clinical, CMC and supply, execution and financing); only non-clinical risk is low. · confidence Medium
Visual 5: risk heat map

Source(s): the risk table above [5] [9] [10] [11]
Top-3 risks. 1. The backbone confound: the effect may be pembrolizumab’s [10]. 2. Manufacturing comparability between production scales [9]. 3. An unfunded registrational trial against a runway to the first half of CY2028 [5] [9].
D. Look-back
Not applicable until settled. The look-back is written at settlement in lookback.md beside this file (06-prompts.md § Settlement).
Readout
Sources
| Kind | Where it comes from | What it is worth | Value (or null) | Tag | Note |
|---|---|---|---|---|---|
bpiq | fetch_company_drugs, fields catalyst_date and catalyst_date_text | The one source every program has. On most rows it is built from period text, so on its own it is the latest plausible date (a ceiling), not an estimate. | 2026-10-19 | [VERIFIED — BPIQ fetch_company_drugs, 2026-10-17] | catalyst_date_text is “October 19, 2026”: it names a day, so catalyst_date_is_exact is true. Unchanged since 2026-08-19. |
ctgov | CT.gov get_trial_details, field primary_completion_date | Independent of the company’s own messaging. Known to the month. It moves when the trial moves. | 2025-04-30 | [VERIFIED — CT.gov NCT06128863, 2026-10-17] | Dates the primary readout, which happened in May 2025. It bounds nothing about this secondary analysis. Study completion 2027-04-30 covers the 24-month follow-up. |
company | fetch_company_press_releases | The company’s most recent dated statement. Also the source of the Date slippage table below. | 2026-10-19 | [VERIFIED — Immutep release 2026-07-24] | ”The full abstract will be published on the ESMO Congress 2026 website on Monday, 19 October 2026”, online at 00:05 CEST. That is 18:05 on Sunday 18 October in New York, so the first US session able to react is 2026-10-19. No later release moved the date [6]. |
congress | data/congresses.json, only when the company has said it intends to present there (02-connectors.md § Data limits) | Answers where the result will be presented. | 2026-10-23/2026-10-27 | [VERIFIED — data/congresses.json, confirmed against esmo.org] | ESMO Congress 2026, IFEMA Madrid. ePoster 3788eP; the display day is not disclosed [49]. |
modelled | Trial arithmetic, see below | The only estimate independent of anyone’s guidance. | 2025-06-30/2025-08-31 | [UNVERIFIED — modelled, default lag] | Uninformative, and recorded anyway: see below. |
The modelled estimate. Registry primary completion 2025-04-30, plus the default lag of two to
four months (01-rules.md rule 34; data/benchmarks/readout-lag.json holds no matching entry),
gives 2025-06-30 to 2025-08-31. That window closed over a year ago. The method dates the trial’s
primary readout, which came on 2025-05-27, faster than the default lag. It cannot date a congress
presentation of a secondary analysis.
An observation this analysis produced but may not write down, carried from 2026-08-19.
EFTISARC-NEO gives a confirmed lag of 27 days: primary completion 2025-04-30, topline 2025-05-27,
both from primary sources. data/benchmarks/readout-lag.json is outside this lane and was not
touched.
Window
| Earliest | Likeliest | Latest | Precision | Confidence |
|---|---|---|---|---|
| 2026-10-19 | 2026-10-19 | 2026-10-19 | DAY | HIGH |
Basis. One moment discloses the numbers: the full abstract online on 2026-10-19 [6]. The ePoster on 23–27 October shows the same content and is not a second readout. Precision is DAY because the company names the day; confidence is HIGH because the trial is complete, the abstract is accepted and the date is a publisher’s calendar.
Corrected after the first lock, kept from the 2026-08-19 version. The window was first written
with latest at 2026-10-27, which counted the congress tail twice and claimed DAY precision over
eight days. The window was narrowed, not relabelled.
Disagreement. CONSISTENT. BPIQ’s 2026-10-19 and the congress’s 23–27 October are two moments of
one event, both stated in the company’s release of 2026-07-24.
Date slippage. Two dated statements, zero slips. Nothing since 2026-07-30 restated or moved the date; the strategy release of 2026-09-11 does not mention it.
| As of | Guidance text |
|---|---|
| 2026-07-24 | ”The full abstract will be published on the ESMO Congress 2026 website on Monday, 19 October 2026” |
| 2026-07-30 | ”EFTISARC-NEO HRQoL ESMO 2026 presentation reiterated; disease-free survival follow-up continues” (BPIQ note) |
Attribution
Status.
| Status | Means |
|---|---|
CONTAMINATED | At least one conflict is confirmed. The stock-direction call below is not presented as attributable to this program alone. |
Conflicts
| bpiq_drug_id | Label | Date | Analysed? | Gap (days) | Confirmed? |
|---|---|---|---|---|---|
| 18203 | IMP761 (LAG-3 agonist) | 2026-12-31 | No | 0 | Yes |
Computed with attributionFor from lib/clustering.mjs over this ticker’s nine pipeline rows at
CATALYST_CLUSTER_MIN_MONTHS = 6, for bpiq_drug_id 17452, on 2026-10-17. Row 13791 (TACTI-004)
no longer carries has_catalyst, so it contributes nothing.
Note. IMP761’s next update is guided to “H2 2026”. With no day named, the computation widens it to 2026-07-01 to 2026-12-31, which contains this readout, so the gap is zero. The conflict is confirmed because this side has DAY precision. Two non-drug events also sit in the stock window and are invisible to the computation. The September-quarter activities report is due by 2026-10-31 under the ASX’s quarterly reporting rule (last year’s came on 2025-10-30), and the FY26 Form 20-F is due by 2026-10-31 (last year’s was filed 2025-10-24). Either can carry cash, burn, root-cause or IMP761 news. The Nasdaq deadline that contaminated the 2026-08-19 window is gone: the ratio change cured it and Nasdaq closed the matter on 2026-10-12 [50]. No move in the window can be credited to the HRQoL abstract alone.
Market and timing for this event
- Plain takeaway. A secondary quality-of-life abstract publishes in two days, on a trial whose real result came out seventeen months ago. The stock trades at US$3.20, 27% below its cash floor of US$4.37, after falling 60% since the last lock. It has no readable options, a Nasdaq line of about US$86,000 a day, and a quarterly report due inside the window.
- Months to this catalyst. 0.1 months: two days, from 2026-10-17 to
readout.window.earliestof 2026-10-19 (rule 23).readout.precisionis DAY, so this is a distance to a known date. - Expected move around this event. A bracket, not a figure, because
../company.mdC.6 records no readable chain. Bracket: roughly ±5% to ±25%. The class averages are +12% / −16% for Phase 2, +9% / −9% for oncology, and an amplitude of 7% for single-arm designs[WEB ESTIMATE — IQVIA 2024][51]. They are measured on primary readouts, and this is not one. The specific facts outrank them: the median reaction to this ticker’s eight comparable data events is +1.8%, while the ADS now trades about US$86,000 a day, so modest order flow moves it 5–10%. - Nearest comparable past reaction.
../company.mdC.7’s 2025-10-20, −1.68%: the same trial’s full primary data at ESMO 2025, already public in headline. It is the closest analogue because it is the same trial, the same congress and the same information structure. The 2026-07-24 acceptance of this very abstract moved the stock −2.56%. The 2026-04-15 orphan designation, +80.65%, is the reminder that sarcoma news can move this stock violently; it was a regulatory fact, not data. - Materiality.
../company.mdC.2 records this program as meaningful at the programme level, immaterial at the event level. The stock call is made consistent with the event (rule 27). - Date slippage. Zero slips (Readout, above).
Spot. US$3.20 per ADS, the settled close of 2026-10-16, read from the price cache through
lib/prices.mjs; cited from ../company.md C.4. It is not an intraday figure: the
cache was fetched on 2026-10-17, after that session closed.
Comparison with the superseded record. The 2026-08-19 record locked US$0.40 on the old basis of 1 ADS = 10 ordinary shares. Times 20, that is US$8.00 on today’s basis. Today’s US$3.20 is 60% lower. The 2026-08-19 bar in the cache reads 0.3964 because an intraday price was frozen there; the source’s close for that day is 0.39 (7.80 on the new basis).
Cash floor.
| Cash floor (USD per share) | Cash, debt, quarterly burn (as of) | Event date | Economic share count | Residual pipeline value | Tag |
|---|---|---|---|---|---|
| US$4.37 per ADS | Cash US$47.93M (A$68.87M at 0.69588); debt-like items US$5.23M (deferred manufacturing accrual and leases, A$7.51M); burn US$8.35M per quarter (A$12M, modelled); as of 2026-06-30; 1.22 quarters to the event | 2026-10-19 | 7,452,053 ADS-equivalents | US$0: no other C.2 row is rated meaningful (every unanalysed row is unfilled) | Cash and debt [VERIFIED — FY26 annual report]; FX [WEB ESTIMATE — ECB reference rate via frankfurter, 2026-10-16]; burn [UNVERIFIED — modelled from guidance]. Computed by cashFloor in lib/edge.mjs |
Scenario prices
| Scenario | Low | High | Anchors (each named, tagged, with its kind) | Basis |
|---|---|---|---|---|
| Positive | US$3.05 | US$4.00 | 1. own_past_moves: median window move of the eight clean, non-registrational data events in C.7, +1.81%, implying US$3.26 [VERIFIED — data/prices/IMMP.json via lib/prices.mjs; event dates from BPIQ and the press feed]. 2. cash_floor: US$4.37, from cashFloor above [VERIFIED — FY26 report; burn UNVERIFIED — modelled] | The low edge is the price if the abstract just meets the positive definition, the “met expectations” bucket. It sits 5% below spot because three of this ticker’s last four positive data events closed lower (2025-10-20 −1.7%, 2026-06-04 −7.2%, 2026-07-24 −2.6%). The high edge is the “significantly exceeded” bucket: quality of life improved, with a release that adds follow-up or a funded trial. It stops below the cash floor; the +80.65% orphan-designation move is the ticker’s maximum and is not used. Class calibration: the +12% Phase 2 average [WEB ESTIMATE — IQVIA 2024] is not applied at full weight, because this is a secondary analysis. |
| Miss | US$2.30 | US$3.00 | 1. cash_floor: US$4.37 [as above]. 2. own_past_moves: the worst comparable data-event window, 2026-06-04, −7.23%, implying US$2.97; and the reaction to the 2026-09-11 strategy release, −30% over the next ten sessions (0.37 to 0.26), implying US$2.24 [VERIFIED — data/prices/IMMP.json via lib/prices.mjs] | The whole row sits below the cash floor. Three reasons. The floor counts burn only to 2026-10-19, while the company plans to spend its cash on efti trials to 2028 and returns none. The market already values the company 27% below the floor. And the ADS line has slid 32% since the ratio change. A meaningful deterioration in quality of life would be new negative information about the one property the regimen’s case rests on, in one of the two indications left. The miss sits deeper than the positive lifts, as the Phase 2 ratio of 1.3 suggests [WEB ESTIMATE — IQVIA 2024]. |
Expectation benchmark. Quality of life maintained through the neoadjuvant period, which is what
the sponsor’s decision to submit and announce the abstract implies investors already expect. Beating
it means global health status improved, or a release adding a funded next step [UNVERIFIED — judgement, from A.1's payer and safety rows].
Expected value. 0.85 × US$3.525 + 0.15 × US$2.65 = US$3.394, +6.05% against spot US$3.20. Method: our probability applied to the midpoint of each range. This is arithmetic, not advice, and not a price target.
Break-even probability.
| Break-even point | Break-even range (low–high) | Our probability (band) | Clearance (pp) | Call (callFromBands) | Evidence for the gap (each named and tagged) |
|---|---|---|---|---|---|
| 62.9% | 20.0%–120.0% | 85% (72–92%) | none | no-edge | none |
Computed by breakEven and callFromBands in lib/edge.mjs. The band [72, 92] overlaps the range
[20.0, 120.0], so the call is no-edge whatever the evidence. The range’s top sits above 100%: at
both low edges, even a certain positive would not justify today’s price, because the positive low
(US$3.05) sits below spot. The expected value is above spot, but the band test does not clear, and
rule 42 lets the test, not the expected value, decide.
What a positive result can be worth.
| Value at approval (low / base / high) | Ceiling price | Allowance (1.5x, or 3x with a named exception) | Ratio to market cap |
|---|---|---|---|
| US$36M / US$262.5M / US$960M | US$70.70 | 1.5x: US$104.46 (3x would be US$205.71; no exception claimed) | 5.8334 |
Computed by commercialCeiling in lib/edge.mjs from B.4a, an economic share of 1.0 (B.4d), the
2–5 sales multiple [UNVERIFIED — default] and a 52.4% probability of approval after a positive
Phase 2 [WEB ESTIMATE — BIO/Informa/QLS 2021], over 7,452,053 ADS-equivalents and a US$23.58M
market capitalisation (../company.md C.4). The 1.5x multiplier is a default
[UNVERIFIED — default]. The positive high of US$4.00 sits far under the cap. The ratio is large
because the company is valued below its cash, not because this catalyst could unlock the value.
Run-up
No run-up call. This is not rule 39. readout.precision is DAY and readout.confidence is HIGH,
so the date_confidence driver would score 100. The call is withheld because no exit rule can
resolve after the entry. The entry would be this lock: 2026-10-17, at the 2026-10-16 close. The
latest permitted exit, T-1 trading day before readout.window.earliest of 2026-10-19, is
2026-10-16 itself. T-2 is 2026-10-15 and T-5 is 2026-10-12. Every exit in EXIT_RULES falls on or
before the entry’s own price date, so the holding period is zero or negative. resolveExit in
lib/runup.mjs returns null against this cache for the same reason: its last bar predates the
window. A run-up band from such a position would be a band of nothing. The field is declared in
not_carried_over (05-prediction-protocol.md § Holes are declared, never filled).
Why it happened. The T-1 cadence gate opened on 2026-09-19. This refresh runs four weeks later, two days before the readout. A position “has to exist before the window opens” (rule 35), and two days before a Monday readout, with no trading session left, it cannot.
The superseded record’s run-up call is still live history. It entered at US$0.40 on 2026-08-19
with a T-5 exit, which resolves to 2026-10-12 (close US$3.67, new basis). Settling it needs a
spot_scale of 20 for the ratio change effective 2026-09-28; on that basis the move is about −54%.
That is for the settlement to compute, from the cache, when asked.
Priority score not computed · formula_version not applicable
Settlement. Not applicable: no run-up call is locked on this record.
Verdict
What I would do. Watch.
Why. The date is certain and the event carries little information: a quality-of-life poster on a 40-patient trial whose result is seventeen months old. What decides this program now is whether a randomised sarcoma trial gets designed and funded for 2H CY2027, and whether the 200 L product behaves like the product that worked. The stock already trades 27% below its cash floor, so the market prices the whole pipeline below zero; a favourable poster is unlikely to change that on its own.
What would change this. To the upside: a funded or partnered randomised trial in soft tissue sarcoma, or a completed root cause analysis showing the 200 L product restores earlier activity. To the downside: a reported meaningful deterioration in quality of life, or an equity raise at a price this far below cash.
What to watch.
- 2026-10-19, 00:05 CEST (Sunday 18:05 in New York): the full abstract on the ESMO 2026 website. Read the instrument, the completion rate of the questionnaire and the timepoints.
- 2026-10-23 to 2026-10-27: ESMO Congress 2026, ePoster 3788eP, and any Immutep release.
- By 2026-10-31: the September-quarter activities report (cash, burn) and the FY26 Form 20-F.
- Undated: completion of the TACTI-004 root cause analysis; any IMP761 update (H2 2026).
- 2026-11-27: the annual general meeting.
- 2027-04-30: EFTISARC-NEO study completion, the first point where disease-free survival can be read.
Locked prediction
- Outcome-direction (will the readout succeed on its primary endpoint?): positive —
probability 85%, band 72–92%
[UNVERIFIED — modelled]. This is the probability that the settlement definition below is met: the abstract, ePoster or Immutep release reports quality of life maintained or improved, with no statistically significant and no clinically meaningful deterioration. It is high for four reasons. No grade 3 or higher toxicity was attributed to either study drug. AIPAC, a randomised trial of efti, found global health status sustained on efti and worse on placebo [22]. The regimen adds injections to visits already scheduled. And the sponsor chose to submit and announce this abstract. It is capped below 90 for three reasons: the endpoint is unregistered, the instrument is undisclosed, and nine weeks of therapy around radiotherapy and surgery can produce a real dip at one timepoint, which in 38 patients could reach statistical significance. Nothing in this sweep moved the figure from the 2026-08-19 value. No third party has published a probability on this event. - Base rate 24.6% (to the next phase, BIO 2021 Figure 2 p. 7, Oncology) — distance +60.4 pp, because the base rate counts Phase 2 programs that advance to Phase 3, while this definition asks only whether reported quality of life did not deteriorate meaningfully, in a trial whose efficacy endpoint is already met and whose safety record is clean.
- Stock-direction (which way do the shares move?): no-edge —
confidencenone — window 2026-10-19 to 2026-11-03, basis: opens when the abstract publishes and closes one week after the congress ends. Materiality, per rule 27:../company.mdC.2 records this program as meaningful at the programme level and immaterial at the event level, and the call follows the event. Attribution, per rule 36: CONTAMINATED by IMP761’s H2 2026 window, with a quarterly report and the 20-F also due inside the window. - Break-even probability 62.9%, range 20.0–120.0% — clearance none — gap evidence: 0 items
- Cash floor: US$4.37 per ADS
- Scenario prices: positive US$3.05–US$4.00 · miss US$2.30–US$3.00
- Commercial ceiling: US$70.70 — positive high allowed up to US$104.46
- Expected value: US$3.394, +6.05% against spot US$3.20
- Run-up: No run-up call. Not rule 39: no exit rule resolves after the entry (see Run-up).
- Settles on the publication of the EFTISARC-NEO HRQoL abstract on the ESMO Congress 2026 website on 2026-10-19 and ePoster 3788eP at the congress. Positive is defined as: the abstract, ePoster or accompanying Immutep release reports health-related quality of life maintained or improved from baseline through the neoadjuvant period, with no statistically significant and no clinically meaningful deterioration (at least 10 points on a 0–100 EORTC QLQ-C30-type global health status scale, or the stated equivalent on the instrument used) in the primary quality-of-life measure reported. A result presented as mixed, a clinically meaningful deterioration on the headline measure, or a withdrawn presentation settles as a miss. The definition is carried word for word in substance from the superseded record, so the two records are scored on the same test.
- Locked: yes · Settled: no
Program data-quality flags
- Price-cache splice (named data defect).
data/prices/IMMP.jsonholds two price scales: bars to 2026-09-25 on the old basis (1 ADS = 10 ordinary), bars from 2026-09-29 on the new basis (1 ADS = 200 ordinary). 2026-09-28, the effective date, is a null bar although Nasdaq counted it as a trading day. 2026-09-14 is a lone new-basis bar (6.60, volume 25,415) between two old-basis bars (0.37 and 0.33). The fetch of 2026-10-17 reported that the source now returns the old bars at 20 times their stored values, and the fetcher never overwrites. Handling here: the 52-week range in../company.mdC.4 uses an adjusted copy (old bars × 20, 2026-09-14 left as is); every C.7 event window lies wholly on one side of the change; spot is a new-basis bar; the run-up is withheld for an unrelated reason, so no run-up driver reads the splice. The cache was not repaired: it is outside this lane. - Corporate action confirmed from primary sources. The ratio change from 1:10 to 1:200, effective 2026-09-28, is stated in the company’s 6-K of 2026-09-22 [36] and confirmed as completed in the 6-K of 2026-10-14 [50]. Ordinary shares unchanged at 1,473,721,306.
- The superseded record needs a
spot_scaleof 20 at settlement. Its spot (US$0.40), scenario prices and run-up entry are on the old basis. - Intraday bar frozen in the cache: 2026-08-19 stored at 0.3964 on volume 44,352, against a source close of 0.39.
- Open Targets answered. Blocked on 2026-08-19 with
Rate limit exceeded for client: global; on 2026-10-17 it returned the three entities and a follow-up association query. - PubMed’s null-authors bug did not fire. All ten articles returned complete author lists.
- No EFTISARC-NEO publication in PubMed, seventeen months after the primary endpoint. A real absence, not a connector failure.
- A cited review contains a factual error. Ibrahim et al. 2023 [40] states that “two LAG-3-directed agents (eftilagimod alpha and relatlimab) have been approved in combination with programmed death-1 (PD-1) inhibitors”. It has not been approved anywhere [29]. The review is cited here only for the class landscape.
- The catalyst’s endpoint is not registered on NCT06128863, and the instrument is undisclosed, so the settlement definition names a threshold generically.
- CT.gov lists no investigators for NCT06128863, and the TACTI-004 record (NCT06726265) still reads “active, not recruiting” with a 2027-06 primary completion, seven months after the trial was stopped.
- No conflict-of-interest statements were retrievable from PubMed for any person in A.2b.
- Secondary relays. The 2025-10-20 and 2025-11-13 Immutep releases are cited through Benzinga’s relay of the GlobeNewswire text, because GlobeNewswire returned HTTP 403 to a direct read on 2026-10-17.
- Correction carried into this version: SARC032’s design. The 2026-08-19 version called SARC032 a “randomised Phase 3” and dated its Lancet paper 2024-09-14. The Lancet abstract describes “an open-label, randomised clinical trial” with 143 patients randomised, and PubMed dates it 2024-11-12 [10]. Both are corrected here.
Sources
[1] Immutep and Dr. Reddy’s Laboratories, licensing agreement announcement, 2025-12-08 — https://announcements.asx.com.au/asxpdf/20251208/pdf/06t2zvhhpr4wp1.pdf [2] Atkinson V et al., Eftilagimod alpha plus pembrolizumab in metastatic melanoma, J Immunother Cancer 2020 — https://doi.org/10.1136/jitc-2020-001681 [3] ClinicalTrials.gov, NCT06128863 (EFTISARC-NEO), read 2026-10-17 — https://clinicaltrials.gov/study/NCT06128863 [4] Immutep, FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, 2026-04-15 — https://www.globenewswire.com/news-release/2026/04/15/3274356/0/en/Immutep-Receives-FDA-Orphan-Drug-Designation-for-Eftilagimod-Alfa-in-Soft-Tissue-Sarcoma.html [5] Immutep, FY26 Annual Report including financial statements, Form 6-K Exhibit 99.1, filed 2026-09-02 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526379062/d435000dex991.htm [6] Immutep, Abstract accepted for presentation at ESMO Congress 2026, 2026-07-24 — https://www.immutep.com/immutep-announces-abstract-accepted-for-presentation-at-the-european-society-for-medical-oncology-esmo-congress-2026/ [7] BIO, Informa Pharma Intelligence and QLS Advisors, Clinical Development Success Rates 2011–2020, February 2021 — https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf [8] Immutep, Translational data and pathologic response rates from EFTISARC-NEO at CTOS 2025, 2025-11-13 (secondary relay of the company release) — https://www.benzinga.com/pressreleases/25/11/g48831052/translational-data-and-significant-pathologic-response-rates-from-eftisarc-neo-phase-ii-highlighte [9] Immutep, Focused development strategy for eftilagimod alfa, Form 6-K Exhibit 99.1, 2026-09-11 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526389402/d127093dex991.htm [10] Mowery YM et al., Pembrolizumab, radiation therapy and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032), Lancet 2024 — https://doi.org/10.1016/S0140-6736(24)01812-9 [11] Immutep, TACTI-004 Phase III to be discontinued following futility analysis, 2026-03-13 — https://www.globenewswire.com/news-release/2026/03/13/3255426/0/en/TACTI-004-Phase-III-Study-in-First-Line-NSCLC-to-be-discontinued-following-Futility-Analysis.html [12] Immutep, Efti with radiotherapy and pembrolizumab meets primary endpoint in Phase II for soft tissue sarcoma, 2025-05-27 — https://www.immutep.com/detail/immutep-s-efti-with-radiotherapy-keytruda-r-pembrolizumab-meets-primary-endpoint-in-phase-ii-for-soft-tissue-sarcoma.html [13] Immutep, Positive data from Phase II trial in soft tissue sarcoma presented at CTOS 2024, 2024-11-14 — https://www.immutep.com/detail/positive-data-from-phase-ii-trial-in-soft-tissue-sarcoma-presented-at-ctos-2024-annual-meeting.html [14] ClinicalTrials.gov, NCT03092323 (SU2C-SARC032) — https://clinicaltrials.gov/study/NCT03092323 [15] ClinicalTrials.gov, NCT06726265 (TACTI-004) — https://clinicaltrials.gov/study/NCT06726265 [16] ClinicalTrials.gov, NCT02614833 (AIPAC) — https://clinicaltrials.gov/study/NCT02614833 [17] ClinicalTrials.gov, NCT03625323 (TACTI-002) — https://clinicaltrials.gov/study/NCT03625323 [18] ClinicalTrials.gov, NCT04811027 (TACTI-003) — https://clinicaltrials.gov/study/NCT04811027 [19] ClinicalTrials.gov, NCT05747794 (AIPAC-003) — https://clinicaltrials.gov/study/NCT05747794 [20] ClinicalTrials.gov, NCT02676869 (TACTI-mel) — https://clinicaltrials.gov/study/NCT02676869 [21] Al-Batran SE et al., Eftilagimod alpha and avelumab in a phase I trial, ESMO Open 2023 — https://doi.org/10.1016/j.esmoop.2023.101623 [22] Wildiers H et al., AIPAC: paclitaxel plus eftilagimod alpha in HR+ metastatic breast cancer, Clin Cancer Res 2024 — https://doi.org/10.1158/1078-0432.CCR-23-1173 [23] PubMed search “eftilagimod”, 10 results, 2026-10-17 — https://pubmed.ncbi.nlm.nih.gov/?term=eftilagimod [24] Immutep, Systemic immune activation with eftilagimod alfa associated with increased overall survival, 2026-05-28 — https://www.globenewswire.com/news-release/2026/05/28/3302799/0/en/systemic-immune-activation-with-eftilagimod-alfa-associated-with-statistically-significant-increased-overall-survival-in-late-stage-cancer-patients.html [25] FDA Purple Book search, read 2026-10-17 — https://purplebooksearch.fda.gov [26] Open Targets Platform, LAG3 (ENSG00000089692) and soft tissue sarcoma (MONDO_0018078) evidence, read 2026-10-17 — https://platform.opentargets.org/evidence/ENSG00000089692/MONDO_0018078 [27] Giri VK, McDermott DF, Zaemes J, The emerging role of LAG-3 targeting in solid malignancies, Cancer 2025 — https://doi.org/10.1002/cncr.35892 [28] DailyMed, KEYTRUDA (pembrolizumab) label, published 2026-07-24 — https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287 [29] ChEMBL, CHEMBL4594557 (eftilagimod alfa), read 2026-10-17 — https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594557/ [30] Forster M et al., Eftilagimod alpha with pembrolizumab in second-line HNSCC, Clin Cancer Res 2024 — https://doi.org/10.1158/1078-0432.CCR-24-0473 [31] Wiśniewska A et al., LAG-3 in (auto)immunity and cancer, Autoimmun Rev 2026 — https://doi.org/10.1016/j.autrev.2026.103992 [32] Immutep, Clinical update in 1st line NSCLC: INSIGHT-003 and TACTI-004, 2026-07-13 — https://www.globenewswire.com/news-release/2026/07/13/3326130/0/en/immutep-provides-clinical-update-in-1st-line-nsclc-positive-mature-overall-survival-data-from-insight-003-and-update-from-tacti-004.html [33] Immutep, Primary endpoint met in EFTISARC-NEO and data presented at ESMO Congress 2025, 2025-10-20 (secondary relay of the company release) — https://www.benzinga.com/pressreleases/25/10/g48299584/primary-endpoint-met-in-eftisarc-neo-phase-ii-evaluating-neoadjuvant-efti-in-soft-tissue-sarcoma-a [34] Czarnecka AM et al. (incl. Teterycz P), Long-term efficacy of radical treatment of clear cell sarcoma, Eur J Surg Oncol 2026 — https://doi.org/10.1016/j.ejso.2026.111485 [35] G-BA, Nutzenbewertungsverfahren zum Wirkstoff Olaratumab (Weichgewebesarkom), decisions 2017-05-18 and 2020-01-16 — https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/268/ [36] Immutep, Change to American Depositary Share ratio, Form 6-K Exhibit 99.1, 2026-09-21 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526397189/d79097dex991.htm [37] O’Byrne K et al., TACTI-004 trial design, Future Oncol 2025 — https://doi.org/10.1080/14796694.2025.2597404 [38] Krebs MG et al., Eftilagimod alpha with pembrolizumab in second-line NSCLC, JTO Clin Res Rep 2024 — https://doi.org/10.1016/j.jtocrr.2024.100725 [39] Immutep, Quarterly Activities Report Q4 FY26, 2026-07-30 — https://www.globenewswire.com/news-release/2026/07/30/3335983/0/en/immutep-quarterly-activities-report-q4-fy26.html [40] Ibrahim R et al., LAG-3 inhibitors: novel immune checkpoint inhibitors, Biomedicines 2023 (contains a factual error; see flags) — https://doi.org/10.3390/biomedicines11071878 [41] NICE, TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma, 2017-08-09 — https://www.nice.org.uk/guidance/ta465 [42] ICER, assessments list, read 2026-10-17 — https://icer.org/assessments/ [43] CMS, Medicare drug price negotiation, read 2026-10-17 — https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation [44] Milliman, Medicare drug price negotiation: Part B dynamics, 2026 (secondary) — https://www.milliman.com/en-GB/insight/medicare-drug-price-negotiation-part-b-dynamics [45] European Commission, Joint clinical assessments, read 2026-10-17 — https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment/joint-clinical-assessments_en [46] NICE, TA185: Trabectedin for the treatment of advanced soft tissue sarcoma — https://www.nice.org.uk/guidance/ta185 [47] Taiho Pharmaceutical, Yondelis (trabectedin) listed on the NHI price list, 2015-11-26 — https://taiho.co.jp/en/release/2015/20151126.html [48] Pharmaceutical Technology, Eftilagimod alfa forecast citing GlobalData (secondary; rejected input) — https://www.pharmaceutical-technology.com/data-insights/eftilagimod-alfa-immutep-net-present-value/ [49] ESMO, ESMO Congress 2026, Madrid, 23–27 October 2026 — https://www.esmo.org/meeting-calendar/esmo-congress-2026 [50] Immutep, Regains compliance with Nasdaq minimum bid price requirement, Form 6-K Exhibit 99.1, 2026-10-13 — https://www.sec.gov/Archives/edgar/data/1506184/000119312526420840/d36112dex991.htm [51] IQVIA, Inflection Point: How Clinical Trial Results Impact Biopharma Valuations, May 2024 — https://www.iqvia.com/library/white-papers/how-clinical-trial-results-impact-biopharma-valuations